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Abstract 
 
 
 Chirality has significant functional effects in biological system including the central 
nervous system. Due to their unique chirality, endogenous D-amino acids are considered to play 
different roles from their corresponding L-isomers. In the central nervous system, a few D-amino 
acids have been found and they have increasingly gained research interest because their 
localization suggests physiological function such as involvement in learning and memory. A 
well-studied D-amino acid is D-serine that works as a signaling molecule in the nervous system 
and its abnormal concentration can cause some pathological states. However, the other 
endogenous amino acids still require further study to establish their metabolic pathways, 
molecular/cellular functions, and physiological role(s) including pathological effect. These 
endogenous D-amino acids include D-aspartate, D-alanine, and D-glutamate that are found in a 
diverse range of animals. 
 A major challenge in endogenous D-amino acid research is to distinguish D-amino acids 
from abundant L-amino acids. Furthermore, neuronal sample volume is usually limited due to 
heterogeneity of neuronal cells; biochemical compositions of neighboring neuronal cells can be 
different. To overcome these difficulties, capillary electrophoresis (CE) has been used because 
CE requires small sample volume and possesses chiral separation capability. Chiral CE 
separation can be achieved by choosing an appropriate chiral selector and/or chemical additives 
working as a pseudo stationary phase. Another advantage of CE is its compatibility with various 
detection methods. In my thesis research, I have frequently employed laser-induced fluorescence 
(LIF) detection to couple with CE to achieve low limit of detection and reliable quantitative 
analysis. 
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 For identification of D-amino acid, biochemical methods are excellent options. There are 
two enzymes that take D-amino acid as substrate: D-aspartate oxidase and D-amino acid oxidase. 
Combining with CE analysis, D-amino acids can be identified from migration time and enzyme 
digestion. Besides enzymatic treatment, antibody-based D-amino acid identification has been 
used. These biochemical sample treatments provide complementary information to help D-amino 
acid analysis via CE separation and detection. Using these approaches with emerging new 
knowledge, formation and function of these enigmatic molecules have been uncovered. 
 Overall, various chiral CE separation modes have been developed in this study to detect 
D-amino acids in a complex chemical matrix. Sensitive and selective D-amino acid measurements 
have been achieved by employing amino acid derivatization, LIF detection and biochemical 
sample treatment methods besides chiral CE separation. Combining these techniques together, 
identification and quantitation of endogenous D-amino acids have been performed to address the 
presence, localization, and putative roles of D-amino acids in nervous and endocrine systems. 
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Chapter 1 
 
Introduction 
 
 
1.1 Research Motivation 
 Neuroscience, the study of the functioning of the nervous system, is a multidisciplinary 
subject involving biology, chemistry, psychology, computer science, and more. This diversity of 
subjects reflects the fact that the central nervous system (CNS), including the human brain, is an 
extremely complex organ composed of numerous neurons and supportive cells. To understand 
this complex system, it is essential to understand the behavior of neurons at the molecular level; 
it is also important to connect the molecular/cellular detail learned at the single cell level to 
physiological/pathological function. A major challenge in molecular/cellular analysis of the CNS 
is that the CNS contains a large variety of neuronal cells with a remarkably heterogeneous 
cellular environment. Ideally the techniques used in neurochemical analysis are compatible with 
cell-sized sample including their tiny volumes and low analyte abundances. Simultaneously, 
molecular profiles of neuronal cells change spatially and temporally due to neuronal activity, 
including neurotransmitter release and techniques are required to monitor these aspects.  
 The challenges described above must be solved by improvements in analytical techniques; 
these techniques must fulfill the requirements of small sample volumes, high spatial and 
temporal resolution, and low detection limits. To achieve these analytical figures of merit, it may 
not be enough to modify one step because analytical techniques include multiple components: 
sampling methods, chemical and biochemical treatments, instrumental analysis, and data analysis. 
Depending on sample type and desired information, it is obvious that some aspects of an 
analytical approach must be flexible to achieve the desired research objective. For example, 
characterizing signaling molecule in neurons can involve appropriate sampling method for 
neuron releasate before, during, and after neuron stimulation; in this case, effective treatment 
method and measurement technique for the signaling molecules may enhance the corresponding 
peak selectively and obtain quantitative data analysis to find a correlation between the target 
signaling molecule and its stimulation to the corresponding postsynaptic neuron. While this 
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combination is just one example, other combinations are required. Here, the overarching research 
goals are both pursuing novel information related to cell to cell signaling (neurotransmission) but 
also in creating analytical techniques that expand the frontier of future measurement science 
applied to neuroscience. 
1.2 Research Overview 
 To answer questions related to neurotransmission, my first goal has been to improve 
several analytical techniques. Indeed, the Sweedler group has developed many analytical 
techniques to probe novel neurochemical pathways and to follow known pathways
1-3
.  
My primary theme has been to study endogenous D-amino acids in the CNS that play 
important roles in the CNS as cell-to-cell signaling molecules. While many signaling molecules 
are well studied, D-amino acids have not been.  D-amino acids may be overlooked in 
neuroscience because it had been long believed that only L-amino acids were involved in higher 
animal function. Therefore, appropriate analytical techniques for distinguishing chirality have 
not reached their maturity nor have they been applied in neuroscience. Several previous 
Sweedler group members worked on this theme and created several measurement platforms and 
results
4-8
. With the accumulated technical and knowledge as a background, my research effort 
has been focused mainly on free D-amino acids.  The first stage has been to develop analytical 
techniques to distinguish D-amino acid signals from abundant L-amino acids. Due to limited 
sample volumes, capillary electrophoresis (CE) is a key analytical technique of my research 
while chirality and molecular identities of analytes are verified by both analytical and 
biochemical approaches. 
1.3 Thesis Overview 
 The remaining sections of Chapter 1 briefly introduce signaling molecules in the CNS 
and relevant techniques used for studying signaling molecules. Chapter 2 summarizes current 
studies on endogenous D-amino acids, especially in the nervous system. D-Aspartate (D-Asp) is 
mostly discussed while other D-amino acids found in the nervous system and targeted in my 
research are also described. Chapter 3 highlights a significant research project to understand the 
formation and function of D-Asp, and to characterize a novel Aplysia amino acid racemase, as 
well as its enzymatic functions, its distributions and its products. Chapter 4 involves the 
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characterization of the most common L-amino acid, L-Glu, and studies the relationship between 
circadian rhythm and L-glutamate in the suprachiasmatic nucleus of the mouse, and represents a 
collaborative study with Martha Gillette’s group. Chapter 5 describes improvements in D-amino 
acid separations and identification methods that are compatible with CE. This chapter also 
discusses the CE analyses of D-amino acid-containing peptides both while an intact peptide and 
after the peptide is digested to form D-amino acid residues. Chapter 6 presents work D-glutamate 
in Aplysia californica central nervous system. Chapter 7 discusses quantitative analyses of D-
alanine in islets of Langerhans of rat pancreas.  The end result of this work is new information on 
D-amino acids and their functions in the brain. 
1.4 Signaling molecules in the nervous system 
 Cell-to-cell communications between neurons uses electrical signaling or chemical 
signaling, with the chemicals termed neurotransmitters and neuromodulators. Neurotransmitters 
are molecules that convey signal from a presynaptic neuron to a postsynaptic neuron. To be a 
neurotransmitter, a signaling molecule should fulfill the following criteria
9
: 
1. The molecule is present and synthesized in the presynaptic neuron. 
2. The molecule is released from presynaptic terminal into the synaptic cleft upon membrane 
depolarization. 
3. Depolarization of postsynaptic membrane is induced through a receptor or an ion channel. 
4. The molecule is removed from the synaptic cleft by uptake or degradation. 
Classical neurotransmitters include L-glutamate, acetylcholine, serotonin, dopamine, L-aspartate, 
glycine, and γ-aminobutyric acid (GABA)10. These neurotransmitters play different roles and are 
localized to specific regions of the CNS, and have a range of release characteristics
11, 12
. Besides 
classical neurotransmitters, there are other categories of neurotransmitters like neuropeptides
13, 14
. 
Neuromodulators have one or more different characteristics from neurotransmitters such as 
changing the profile of membrane depolarization during neuron firing as a co-agonist of the 
neurotransmitter receptor, involving secondary messengers, and being released other than 
presynaptic terminal of neurons
15, 16
, with the modulation of neuronal activity often being of 
much longer duration.  The classic group of neuromodulators is the neuropeptides.  Intriguingly, 
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some molecules, including classical transmitters and peptides, can act as both depending on 
location and circumstances, and so such categorizations are not absolute.  
 Recently, D-amino acids have gained attention as putative neurotransmitters or 
neuromodulators in the CNS. D-Serine is a well-studied D-amino acid that acts on the N-methyl 
D-aspartate receptor
17-19
. Other endogenous D-amino acids include D-Asp, D-alanine, D-glutamate, 
and D-proline that are also reported to be found in animal CNS
20
. 
1.5 Background of analytical techniques used to study for endogenous D-
amino acids 
1.5.1 Capillary electrophoresis (CE) 
 CE is a common separation method to work with tiny sample volumes (nanoliter scale of 
sample consumption per sample injection) and relatively fast separation speed
21-23
 while other 
separation techniques like high performance liquid chromatography (HPLC) are also common
24, 
25
. These separation methods are flexibly coupled with a detection method such as UV 
absorbance, fluorescence, and mass spectrometry. For analysis of D-amino acids in biological 
samples, it is important to consider if the separation method or detection method has an ability to 
distinguish D-amino acids from corresponding L-amino acids. In the case of CE separation for D-
amino acids, CE needs to have chiral separation capability unless the coupled detector, e.g. 
circular dichroism detector, can distinguish chirality.  
One widely used setting for chiral CE separation is cyclodextrin-mediated capillary zone 
electrophoresis (CD-CZE)
26
. CZE separates analytes based on apparent mobility (µapp) of each 
compound that is the sum of electrophoretic mobility (µep) and electroosmotic flow (EOF) (Fig 
1.1): 
µapp = µep + µeof    (1) 
Therefore, migration speed of each analyte is described as: 
ν = µappE = (µep + µeof)E   (2) 
where E is the electric field applied to capillary. EOF depends on the condition of inner surface 
of capillary
27
. In many cases, bare-fused capillary is used for CE and its inner surface is covered 
by silanol (Si-OH) group (Fig 1.2). In neutral to basic pH, deprotonation of silanol group occurs 
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and two layers of cations (fixed and mobile layer) are formed on the deprotonated silanol group 
(Fig 1.3a). Applying high voltage, mobile layer of cations migrates toward cathode and this 
movement causes bulk flow (EOF) (Fig 1.3b). So the same value of µeof is applied to all analytes 
in the same separation condition while µep is affected by the charge and molecular weight of each 
analyte. In a given separation solution, µep can be described as: 
µep = z/(6πηr)     (3) 
where z is the charge of the analyte, η is the viscosity of separation solution, and r is the Stokes' 
radius of the analyte that depends on molecular weight. In neutral to basic pH separation 
condition, µep is usually smaller than µeof, so most analytes migrate toward outlet side of 
capillary although migration speed varies due to µep. On the other hand, EOF is suppressed at 
low pH
28
 by protonating the silanol group such that µep can overcome µeof. EOF suppression can 
be also induced by coating the inner surface of the capillary to give a neutral charge
29
. Once the 
capillary inner surface is completely coated with neutrally charged compound, EOF is strongly 
suppressed regardless of pH of the separation solution. With suppressed EOF, analyte migration 
and separation primarily depend on µep. This type of separation is classified as electrokinetic 
chromatography and its main benefit is a totally different migration pattern from that of CZE. 
 Another CD-modified CE technique is micellar electrokinetic chromatography (MEKC) 
that uses surfactant molecules. In the separation solution, surfactant molecules form micelles 
which work as a pseudo-stationary phase
30
. With CD in the separation solution, the pseudo-
stationary phase helps chiral separation of analytes even if micelles are formed by achiral 
surfactant molecules. 
 CE can be operated even with solutions using non-aqueous solvent. Non-aqueous CE 
(NACE) is a useful alternative if hydrophobic CD or other chemical additives are used for chiral 
separations
26
. Furthermore, solvent difference affects some physical and chemical parameters of 
chemicals in separation solution like binding constant of analyte to a CD
31-33
. These 
characteristics make NACE as an alternative separation mode of conventional aqueous CE 
separation methods.  
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1.5.2 Laser-induced fluorescence (LIF) and amino acid derivatization 
 As is mentioned in the section above, CE can be coupled with variety of detectors. The 
most widely used detection method is UV absorbance since this detection method requires 
relatively easy and inexpensive instrumentation and is fairly universal; it detects diverse types of 
molecules. More sensitive and selective measurement can be achieved by LIF detection. LIF 
intensity (If) is given as: 
If = cdkIlQf     (4) 
where c is the concentration of the fluorophore, d is the pathlength of excitation, k is the base-ten 
logarithm of the molar absorptivity of the fluorophore, Il is the intensity of the laser, and Qf is the 
fluorescence quantum yield of the fluorophore
34
. Since CE has short pathlength for excitation, it 
is important to choose an appropriate combination of excitation laser and fluorophore. In D-
amino acid analysis, LIF detection can be used when fluorophore is attached because many 
endogenous amino acids do not have chemical structure that can fluoresce. Reactive dyes react 
with amino acids to make them fluorescent molecules. Most of reactive dyes derivatize amino 
acids through reaction with amino group. There are some amine-reactive fluorescent dyes such 
as 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) and 4-(N,N-dimethylaminosulfonyl)-7-fluoro-
2,1,3-benzoxadiazole (DBD-F)
35
 while amine-reactive fluorogenic dyes, such as naphthalene-
2,3-dicarboxaldehyde (NDA)
36
 and 3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde 
(CBQCA)
37
, are useful because fluorogenic dyes are not excited by the excitation wavelength for 
amino acids derivatized with the fluorogenic dye. In addition, there are chiral amine-reactive 
dyes like 4-(3-isothiocyanatopyrrolidin-1-yl)-7-(N,N-dimethylaminosulfonyl)-2,1,3-
benzoxadiazole (DBD-PyNCS)
38
. These chiral dyes form diastereomers when they react with 
amino acid enantiomers. The properties of these dyes are summarized on Table 1.1. 
1.5.3 Biochemical methods 
 It is usually challenging to distinguish one enantiomer from the other corresponding 
enantiomer based on their physical or chemical properties. However, molecules in biological 
systems can distinguish enantiomeric molecules by ligand-substrate binding. Enzyme digestion 
of D-amino acids is a biochemical method to eliminate D-amino acids selectively (Fig 1.4). There 
are two widely known enzymes for D-amino acid digestion: D-aspartate oxidase (DAspO) and D-
amino acid oxidase (DAAO). DAspO performs oxidative digestion for acidic amino acids, i.e. D-
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Asp and D-glutamate, and their N-methyl derivatives like N-methyl D-aspartate
39
. In contrast, 
DAAO can digest D-amino acids other than D-Asp and D-glutamate
39, 40
. With these enzymes, it 
is possible to tell the presence of D-amino acids in target tissue by measuring their enzymatic 
activities. Moreover, these enzymes are used for treating biological samples to identify D-amino 
acid peaks in a separation
41
 or they can be used as D-amino acid detector
42
.  
 Another biochemical approach for D-amino acid analysis involves selective antibodies. 
Even though raising an appropriate antibody is challenging, it is meaningful that spatial 
distribution of a specific D-amino acid can be visualized
43
. It is also possible to have 
immunological sample treatment followed by analysis with a separation method (Fig 1.5)
7
. 
Compared with the enzymatic digestion method, the immunological method has an advantage 
that an antibody can identify a specific D-amino acid without using other analytical methods. 
Meanwhile, the enzymatic method is easier to establish and useful to identify multiple D-amino 
acids when it is combined with a chiral separation method. 
1.5.4  Mass spectrometry-based detection 
 Recent advancement of mass spectrometry (MS) technology gives rich information for 
complex samples to elucidate analyte identities
44-46
. However, MS has difficulty to distinguish 
chiral molecules, especially for enantiomeric pairs, because of their identical molecular mass and 
very similar physicochemical properties. Therefore, to utilize advantages of MS detection for D-
amino acid analysis, MS should be coupled with a separation method like CE so that a separation 
technique can distinguish chirality of analytes which is complementary information of MS 
detection. 
 There are several ionization methods available for MS such as chemical ionization, 
electron impact ionization, electrospray ionization (ESI), and matrix-assisted laser desorption 
ionization (MALDI)
44
. Among these ionization methods, ESI and MALDI are the ones 
commonly used with CE for biological samples due to their soft ionization
44, 47
. ESI can be 
connected on-line with CE so that liquid-phase separation, including CE, can be analyzed by MS 
that requires ionic analytes in gas-phase
48
. Therefore, CE-ESI-MS can use migration time of 
analytes as a parameter while ESI is not compatible with some CE settings such as use of 
separation solution including nonvolatile salts and surfactants
47, 49
. Meanwhile, MALDI is 
usually connected off-line with CE
50
. With off-line MALDI-MS, CE eluent are collected as 
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discrete spots on MALDI sample target with careful instrument operation
51, 52
. Since eluent 
collection of MALDI-MS takes a few tens of seconds c.a. 20 to 30 s
50, 52
, it is difficult to apply 
for enantiomeric molecules that have relatively small differences of migration time. To use 
migration time of analyte during CE separation as an important indicator of chirality, CE-ESI-
MS is easier than CE with off-line MALDI-MS. Thus, D-amino acid study can employ CE-ESI-
MS as a useful analytical method. 
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1.7 Tables and figures 
 
 
Figure 1.1. Illustration of electrophoretic (EP) and EOF forces in CZE. ν: migration speed of 
analyte; µeof: mobility due to EOF; µep: EP mobility; E: electric field applied to capillary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  13 
 
Figure 1.2. Inner surface of bare-fused silica capillary. (Left) a capillary is in dry condition  
and (right) in hydrated condition that is used for CE. 
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Figure 1.3. Bare-fused silica capillary in solution of neutral or basic pH. (a) Two layers of 
cations are formed near the capillary surface and, (b) by applying voltage to the capillary,  
cations at diffuse layer migrate toward cathode and drag solvent molecules. This phenomenon 
causes EOF, bulk flow of solution. 
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Dye λex (nm) λem (nm) Analyte Additional Note 
NDA 440 490 Primary Amine Fluorogenic dye 
CBQCA 450 550 Primary Amine Fluorogenic dye 
Fluorescamine 495 521 Primary Amine Can react with peptides 
DBD-Py-NCS 488 590 Primary Amine Diastereomer formation 
NBD-F 447 558 
Primary and 
Secondary Amine  
DBD-F 453 573 
Primary and 
Secondary Amine  
NBD-PZ 470 541 Carboxylic Acid . 
DBD-ED 447 558 Carboxylic Acid 
 
 
Table 1.1. Candidate dyes for amino acid derivatization. The dyes have excitation 
wavelength that reasonably matches laser light source (442 and 488 nm) used for CE instrument 
described in the following chapters. 
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Figure 1.4. Enzymatic oxidation of D-amino acids. D-amino acids can be oxidized either by 
DAspO or DAAO at the presence of the cofactor, flavin adenine dinucleotide (FAD). 
  
DAAO or 
DAspO 
FAD 
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Figure 1.5. D-Asp antibody eliminates or reduces D-Asp signal intensity in CE-LIF 
detection. (A) Electropherogram of control solution containing 5 μM D-Asp and internal 
standard (I.S.), L-cysteic acid. (B–D) Electropherograms of same sample as in (A) treated with 
decreasing amounts of D-Asp antibodies. The volume ratios of D-Asp antibody to D-Asp are 1:1 
in (B), 1:10 in (C), and 1:100 in (D). Reprinted with permission from Elsevier 
7
. 
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Chapter 2 
 
D-Amino Acids as Signaling Molecules in Nervous and 
Neuroendocrine Systems 
 
This chapter describes the current studies on endogenous D-amino acids in the nervous systems, 
especially D-Asp, to provide background for much of my thesis research and to summarize what 
is known: the reported evidence trying to establish their spatial/temporal localization, their 
metabolic pathways, and their physiological roles. This chapter also includes the studies of other 
D-amino acids related to my research later: D-Ala and D-Glu (Chapters 5 and 6). Since the 
number of reports describing these D-amino acids is limited, the presence of these D-amino acids 
are not understood nor established yet as endogenous amino acids. Finally the basic knowledge 
and the current studies on D-Ser, the most extensively studied D-amino acid, are briefly described. 
Although my thesis research did not perform D-Ser experiments in depth, the large number of D-
Ser studies serves as a mirror to describe next steps for studies on the other endogenous D-amino 
acids. 
 The first section and a part of the last section of this chapter (2.1 and 2.3) are adapted 
from “D-aspartate acts as a signaling molecule in nervous and neuroendocrine systems” co-
authored by Nobutoshi Ota, Ting Shi, and Jonathan V. Sweedler and published in Amino Acids, 
2012, 43 (5): p.1873-1886, DOI: 10.1007/s00726-012-1364-1
1
. The sections 2.1 and 2.3 are 
reprinted with permission from Springer. These sections review the current status of endogenous 
D-aspartate research.  The section 2.2 summarizes current studies on D-Ser, D-Glu, and D-Ala. 
The material is based upon work supported by Award Number R01 NS031609 from National 
Institute of Neurological Disorders and Stroke, Award Number P30 DA018310 from the 
National Institute on Drug Abuse, and Award Number CHE-11-11705 from the National Science 
Foundation.  
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2.1 Endogenous D-Aspartate 
2.1.1 Introduction 
In animals, L-amino acids are ubiquitous and used exclusively for ribosomal protein 
synthesis. Although less abundant, free D-amino acids have been reported in a diverse range of 
invertebrate and vertebrate species
2, 3
. D-aspartic acid (D-Asp) is a D-amino acid that has received 
significant attention because of its presence in animal nervous and reproductive systems
4-11
; 
however, questions about its metabolism, cellular function, biological and physiological roles, 
and pathological significance remain. Investigations of D-Asp in living organisms have involved 
various animals, including cephalopods
4, 12, 13
, gastropods
14-17
, amphibians
18, 19
, reptiles
20, 21
, and 
mammals, including humans
6, 22, 23
. These studies document its widespread occurrence and 
suggest that D-Asp plays important roles throughout the Metazoan.  
In this review, we focus on the more recent reports on D-Asp in animal nervous and 
neuroendocrine systems, from the molecular to physiological levels, emphasizing studies that 
provide insight into its functions. To be considered as neurotransmitter, D-Asp needs to 
demonstrate the following criteria
24
: be present in the presynaptic neuron, be released into the 
synaptic cleft upon stimulation, induce depolarization of the postsynaptic membrane through a 
receptor or an ion channel, and be removed from the synaptic cleft by uptake or degradation. 
Hence, we highlight studies that describe its localization, transport, release and 
electrophysiological responses as these suggest that D-Asp can act as a hormone, transmitter, 
and/or trophic factor, and accordingly, has a significant role in cell-to-cell signaling within the 
nervous system. Where appropriate, we also describe the analytical approaches used in these 
studies as chiral measurement methods are not as common as those used for other neurochemical 
measurements. For an increasing range of cell types, single cell assays
25-27
 now allow a selected 
cell’s small molecule contents to be measured, thus enabling a new range of studies on unusual 
neurochemical pathways, with several of these approaches well suited to examining chiral amino 
acids. 
2.1.2 D-Asp distribution  
D-Asp has been found in the nervous and endocrine tissues of various vertebrate animals 
including the frog
18
, lizard
20
, and chicken
28
. It has also been described in mammals such as 
  20 
mouse
23
, rat
8, 22, 29, 30
, and human
6, 31, 32
. In the nervous system, a transient increase of D-Asp 
occurs during development but its concentration drops to trace levels in adults, at least in the 
chicken
28
, rat
5, 7
 and human
7
. Dunlop may be the first to demonstrate the trend of decreasing 
levels of D-Asp during development by measuring higher levels of D-Asp in the cerebral 
hemispheres of newborn rats as compared to the levels of older animals
5
. The development-
related changes in D-Asp levels showed marked regional differences within the rat central 
nervous system. These regional changes were further characterized using immunohistochemistry 
with an anti-D-Asp antibody
33
, demonstrating that in the rat embryonic brain, D-Asp appears to 
emerge near the hindbrain, and then spread into the forebrain. In terms of its intracellular 
localization, D-Asp was first observed in the cell body of neurons in the outer layer of the neural 
epithelium, and then appeared in the axons once a distinct axonal layer had been established. 
These data support the notion that D-Asp is involved in neuronal differentiation. In an another 
study, D-Asp was suggested to have an important role in development because intense 
immunoreactivity was observed within the cortical plate and subventricular zone of the early 
postnatal rat brain, while the immunoreactivity dropped to almost undetectable levels in adults
34
. 
Moreover, the same study also reported that in all examined brain regions at all ages, D-Asp 
immunoreactivity was restricted to neurons but not to glia, with D-Asp staining observed in both 
neuronal cell bodies and neuronal fiber tracks. 
Concurrently with many of the vertebrate studies, D-Asp was characterized in a number 
of invertebrates, often with similar results. It was reported first in the brain and optic lobes of 
Octopus vulgaris, with D-Asp measurements performed using liquid chromatography and the 
clever approach of selective degradation via the enzyme D-Asp oxidase (DAspO)
4
. Since then, D-
Asp has been reported in the nervous system of other invertebrate animals spanning a number of 
phyla: mollusks such as the cephalopods Sepia officinalis and Loligo vulgaris
35, 36
; 
opisthobranchs such as Aplysia fasciata
14
, Aplysia californica
37
, and Aplysia limacine
17
; 
arthropods such as the crustacean Jasus lalandii
38
; and protochordates, including the tunicate 
Ciona intestinalis
39
 and amphioxus Branchiostoma lanceolatum
40
. D-Asp has also been found in 
reproductive tissues such as the glands of O. vulgaris
36
.  
For endogenous D-Asp characterization, a range of analytical measurement approaches 
have been used, including  chromatographic methods combined with enzymatic D-Asp digestion 
(Fig 2.1). D-Asp localization can be examined by immunostaining with a D-Asp antibody (Fig 
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2.1a). D-Asp quantitation has employed separations such as high performance liquid 
chromatography (HPLC) and capillary electrophoresis (CE) as these can provide chiral amino 
acid separations that enable measurements of each enantiomer
41, 42
. For enhanced confirmation of 
D-Asp peak identity, sample treatment by DAspO digestion
17
 (Fig 2.1b) or via 
immunoprecipitation
43
 can be employed.  
The accumulating evidence on D-Asp distribution in invertebrate animals suggests that D-
Asp is involved in both neuronal and neuroendocrine systems. In neuronal cells of invertebrates, 
D-Asp has been found throughout the cell soma and neuronal processes (Fig 2.1c). Within 
individually assayed sensory neurons of A. californica, D-Asp ratios (D-Asp vs. total Asp amount) 
in the cell soma and in morphologically different parts of neuronal processes were similar
44
, 
although different neurons in the same ganglia contained distinct D-Asp levels
16
. Spinelli and 
coworkers
17
 studied populations of cerebral ganglia neurons of A. limacine and their experiments 
support that D-Asp is found in both the cell soma and synaptosomes. Furthermore, they also 
found higher concentrations of D-Asp in the synaptic vesicles from synaptosomes than in the 
synaptosome preparations as a whole, and higher levels in the synaptosomes than in the cell 
soma, suggesting that D-Asp is indeed concentrated in synaptic vesicles. Similarly, in L.vulgaris 
brain neurons, D-Asp was mostly found in synaptic vesicles; D-Asp concentrations were higher 
in synaptic vesicles than in synaptosomes whereas D-Asp concentrations in whole brain 
homogenates were lower
13
. These studies certainly support the localization of D-Asp to both 
synaptic terminals and synaptic vesicles. 
2.1.3 Biosynthesis of D-Asp 
How is D-Asp formed? Even though dietary uptake of D-Asp produced by 
microorganisms is known to occur, the direct synthesis of D-Asp in animal cells has also been 
confirmed. After more than a decade of reports describing D-Asp synthesis by racemase enzymes 
in bacteria
45
, and D-amino acid transaminases in bacteria
46
 and plants
47
, the biosynthesis of D-
Asp in higher animals was demonstrated in mammalian pheochromocytoma cells (PC12 cells), 
which do not spontaneously uptake extracellular D-Asp
48
. The study used HPLC, DAspO 
digestion, and immunohistochemical staining methods to show that PC12 cells contain D-Asp 
converted from L-Asp; D-Asp levels in these cells and the culture media increased during 
culturing. Since this early study, D-Asp biosynthesis has been studied in other animals and cell 
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types: C. intestinalis
39
, A. limacine
17
, A. californica
16
, S. officinalis
49
, Rana esculenta
50
, and 
several types of mammalian cultured cells
51, 52
. Furthermore, colorimetric analyses with DAspO 
for Rattus norvegicus and L. vulgaris have shown that D-Asp synthesis may occur in the soma of 
neurons because synaptosomes and synaptic vesicles had considerably lower D-Asp production 
compared to that of whole brain
13
. 
Because D-Asp appears in a D-Asp-free environment in cultured PC12 cells
48
, its 
biosynthesis has been hypothesized to occur intracellularly via an Asp racemase, transaminase, 
and/or the racemization of an aspartyl residue of peptides
11, 41
. Putative Asp racemases catalyze 
D-Asp formation using L-Asp as a substrate. Several studies using radiolabeled L-Asp support the 
idea that an Asp racemase is involved in D-Asp production. As examples, [
14
C]- L-Asp was 
incubated in rat embryonic neurons and [
14
C]-D-Asp was detected and accumulated throughout 
the incubation
34
. [
14
C]-D-Asp synthesis from [
14
C]- L-Asp was also observed in cerebral ganglia 
neurons of A. californica
16, 53
, and it was demonstrated that the Aplysia ganglia, which contain 
more neuronal cell soma, produced more [
14
C]-D-Asp than the sheath tissues, which 
predominately contain processes and terminals
53
. The Asp racemase is expected to be pyridoxal-
5’-phosphate (PLP)-dependent because aminooxyacetic acid, an inhibitor of PLP-dependent 
enzymes, clearly inhibited [
14
C]-D-Asp production in rat embryonic neurons
34
.  
Indeed, an Asp-specific, PLP-dependent racemase has been purified from the foot muscle 
of the bivalve, Scapharca broughtonii
15
 and has since been cloned
54
, although the presence of 
this racemase in the Scapharca nervous system has not been determined. Two recent studies 
have further clarified the enzymes present. Kim and colleagues
55
 characterized an Asp racemase 
found in mouse brain; this was the first Asp racemase identified in an animal nervous system. 
This specific racemase is PLP-dependent and is expressed in brain, heart, and testes, as well as 
moderately expressed in the adrenal glands. This same study also demonstrated that this 
racemase is correlated to neurogenesis, indicating that D-Asp may work as a trophic factor (Fig 
2.2a, b). We recently reported a PLP-dependent racemase from the A. californica central nervous 
system
56
; interestingly, this racemase is unique as it catalyzes both Asp and serine (Ser) 
racemization. The localization of this racemase corresponds to cells that we had previously 
shown contain both D-Asp and D-Ser, suggesting that both activities are functional within these 
neurons (Fig 2.2c, d).  
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When comparing the known Asp racemase sequences, those belonging to S. broughtonii 
and A. californica share more than a 50% sequence identity, whereas the mouse Asp racemase 
sequence appears distinct from the molluscan Asp racemases
56
.  The mouse Asp racemase 
sequence homology suggests it is related to glutamate-oxalacetate transaminases
55
. These 
sequence differences may indicate that multiple Asp racemase families exist in the central 
nervous system of different animals. 
Other possible biosynthesis pathways have been suggested for D-Asp, either via a PLP-
dependent transaminase or degradation of D-Asp-containing peptides
41
; however, these may not 
be major D-Asp biosynthesis pathways in animals. For example, D-Asp can be produced by what 
is normally considered a side reaction of amino acid transaminases. Although mitochondrial 
transaminases from chicken and Escherichia coli convert small amounts of L-Asp into D-Asp, 
most of the L-Asp is converted to oxalacetate
57-59
. Perhaps some D-Asp may be produced in 
animals by a D-amino acid transaminase that accepts other D-amino acids as an amino group 
donor in order to convert oxaloacetic acid into D-Asp; this type of enzymatic reaction has been 
reported in plants
60
. D-aspartyl residues form due to spontaneous isomerization of L-aspartyl 
residues in proteins
61
, which would result in free D-Asp release via protein degradation. It is not 
obvious how such a formation pathway would be cell specific and thus account for the observed 
cellular distributions of D-Asp. Regardless, the existence and enzymatic characterization of two 
distinct neuronal Asp racemases documents the ability of D-Asp to be formed under enzymatic 
control. 
2.1.4 Uptake and transport of D-Asp 
D-Asp uptake has been found to occur in the nervous systems of vertebrates and 
invertebrates, with the uptake and accumulation from the extracellular environment 
demonstrated in experiments using radiolabeled D-Asp. As one example, a rat hippocampal slice 
incubated in media containing [
3
H]-D-Asp showed an increase of cellular [
3
H]-D-Asp in a dose-
dependent manner
62
. Similarly, the uptake of D-Asp in rat neuroendocrine tissues was shown by 
the accumulation of [
14
C]-D-Asp in pineal and pituitary glands after intravenous administration 
of [
14
C]-D-Asp
63
. In A. californica, uptake and accumulation of [
14
C]-D-Asp was observed in 
both the central nervous system and in individual isolated and characterized neurons
53
. Although 
its distribution was reported to be neuronal, several studies of astrocytes indicate that D-Asp 
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occurs in glia also
64-66
. Takigawa and coworkers
67
 showed that exogenous D-Asp taken up by rat 
pinealocytes dispersed into their cytoplasm but not into their nuclei; the exogenous and 
endogenous distribution patterns were measured and found to be the same. 
D-Asp uptake may depend on a high-affinity L-glutamate (L-Glu) transporter that can take 
up extracellular D-Asp into cells efficiently while the transporters also uptake L-Glu and L-Asp, 
which compete with D-Asp. The L-Glu transporter is Na
+
-dependent, has a similar affinity to D-
Asp, L-Asp and L-Glu, and is known to be blocked by DL-threo-beta-hydroxyaspartic acid
68
. The 
sodium- and temperature-dependent preferential uptake of D-Asp over L-Asp has been reported 
in Aplysia also
53
.  Experiments with cultured cells indicate that the L-Glu transporter is 
responsible for D-Asp uptake; PC12 cells that do not express L-Glu transporters showed no clear 
change in cellular D-Asp levels regardless of the extracellular D-Asp concentrations
48, 69
. On the 
other hand, MPT1 cells, which are PC12 variants that express L-Glu transporters, uptake D-Asp 
actively, whereas transporter inhibitors significantly decrease D-Asp uptake
69-71
. It may be that 
different levels of D-Asp are taken up into different tissues because of distinct populations of L-
Glu transporter-expressing cells. We expect that issues concerning D-Asp uptake will be clarified 
by additional studies using cells with a well-defined transporter expression.    
2.1.5 Degradation of D-Asp 
Besides its synthesis, the removal and degradation of a molecule is also important when 
determining if it is a transmitter. D-Asp degradation is likely to occur by the well-known  enzyme, 
DAspO, found throughout the Metazoan. DAspO oxidatively degrades dicarboxylic D-amino 
acids (D-Asp and D-Glu, and N-methyl-D-Asp (NMDA)), while most other D-isomers of neutral 
and basic amino acids are degraded by the enzyme D-amino acid oxidase (DAAO)
72, 73
. The 
amino acid sequence of DAspO from beef kidney showed more than a 40% homology with that 
of pig kidney DAAO
74
, thus it is not surprising that both enzymes require flavin adenine 
dinucleotide as a cofactor
2
. The gene sequence of DAspO has been reported for bovine and 
mouse kidney, and human brain, with cDNA clones expressed
75-77
. In addition, DAspO genes 
have been identified in C. elegans and cDNA clones were characterized recently
78, 79
. 
Interestingly, there are three DAspO genes in C. elegans, and each showed different levels of 
oxidation activity. The authors hypothesize that the C. elegans DAspOs are localized in different 
subcellular locations because each of these genes have different signal peptide sequences
79
. One 
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C. elegans DAspO is expected to locate in the peroxisome, which is the same cellular organelle 
as the DAspO localization for human and rat liver
79, 80
. Perhaps this has been conserved as 
DAspO (as a product of its enzymatic oxidation) because it generates hydrogen peroxide, a toxic 
molecule that is utilized in peroxisome.  
The DAspO activity correlates to the presence of D-Asp. Mouse liver DAspO has shown 
increased activity after the administration of D-Asp
81, 82
. Similarly, yeast DAspO activity was 
increased, and DAspO expression induced, by increasing transcription when D-Asp was used as 
the sole nitrogen source in culture media
83, 84
. Meanwhile, D-Asp and DAspO distributions in the 
brain and neuroendocrine system of rat appear complementary; high D-Asp levels have been 
found where DAspO levels were low and vice versa
9
. Additionally, a magnitude higher activity 
of DAspO has been reported in postsynaptic membranes of R. norvegicus and L. vulgaris when 
compared with DAspO activity in the brain cytosol
13
. Thus, D-Asp appears to have a function in 
locations where DAspO levels are low enough so that D-Asp is not immediately eliminated.   
2.1.6 D-Asp release  
D-Asp release has been measured from D-Asp-containing tissues or cells of the 
mammalian brain in a Ca
2+
-dependent manner upon chemical and electrical stimulation
85, 86
; 
these stimulation methods are still widely used, not only for mammalian brain but also for 
neuronal cells of other species (Fig 2.3a, b)
53
. The importance of Ca
2+
 for triggering D-Asp 
release was demonstrated by introduction of ethylene glycol tetraacetic acid (EGTA), a chelating 
agent for Ca
2+
; D-Asp release after exposure to both KCl and EGTA resulted in a magnitude 
smaller D-Asp release than that after KCl exposure only
34
. Preloading D-Asp with radioactive 
labels in the brain slice clearly demonstrated that intracellular D-Asp was released upon chemical 
and electrical stimulation
87-89
. Besides depolarization having been induced by potassium ions or 
acetylcholine (which triggered D-Asp release from rat adrenal slices), nicotine application 
resulted in the depletion of D-Asp in the adrenal slice while L-Glu and L-Asp levels were not 
significantly changed
34
. Norepinephrine is another example of a chemical stimulus for D-Asp 
release used in rat pinealocytes
67
, cells in the pineal gland that contain a significant amount of D-
Asp
90
.  
Savage and colleagues
89
 showed electrical-stimulation-evoked D-Asp and L-Glu release 
from hippocampal slices. In their experiments, more than 90% of the D-Asp and L-Glu releasates 
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were Ca
2+
-dependent. They also reported that D-Asp release was dramatically decreased by 
treatment of the hippocampal slice with either a synaptic vesicle toxin or magnesium, and 
moderately decreased with voltage-sensitive Ca
2+
 channel antagonists. Significant decrease of D-
Asp release with the application of a synaptic vesicle toxin was also observed in rat cerebellar 
granule cells
91
 and in cultured PC12 cells
92
. Studies with A. limacina and L. vulgaris also 
indicated that D-Asp accumulated in synaptic vesicles and was released upon stimulation
13, 17
, 
and that the vesicles were involved in the transport of D-Asp from one ganglion to another in A. 
californica
16
. These studies support that D-Asp is stored in synaptic vesicles and is released by 
exocytosis (Fig 2.3c–g). 
However, spontaneous and continuous D-Asp release that is independent of exocytosis 
has also been proposed. This hypothesis is supported by several studies on cultured mammalian 
cells. PC12 cells, as discussed above in the Biosynthesis of D-Asp section, produce D-Asp within 
the cells but cannot uptake extracellular D-Asp. Through PC12 culturing, it was observed that 
intracellular and extracellular D-Asp levels increased without any specific stimulation to the 
cells
48
. Similar results were observed in MPT1 cell cultures in which D-Asp levels increased over 
the duration of the culturing period even though initially, no D-Asp was in the media
70
. In 
another study from the same group
93
, D-Asp and dopamine release was compared in PC12 cells; 
upon KCl stimulation, the amount of released dopamine rose after stimulation and stayed at a 
constant level, while D-Asp levels gradually increased independent of the extracellular KCl 
concentration. They also showed that D-Asp release was not sensitive to silencing SNAP-25, a 
protein essential for exocytosis. These results are distinct from the observed reduction of D-Asp 
release in PC12 cells after cleavage of SNAP-25
92
, as well as those from a hippocampal study 
with Ca
2+
 channel antagonists
89
. 
Another pathway for D-Asp release has been proposed via a volume-sensitive organic 
anion channel (VSOC); this transmembrane protein channel opens upon hypotonic stimulation. 
Putative VSOC inhibitors reduced D-Asp release from PC12 cells in hypotonic media
93
.  
Overall, these release studies indicate that there may be multiple release pathways: via 
exocytosis of D-Asp-containing vesicles, spontaneous and continuous D-Asp release, and VSOC-
dependent release. Furthering our understanding of these putative D-Asp release pathways 
obviously requires additional investigation. 
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2.1.7 Molecular and cellular functions of D-Asp 
What does D-Asp do in the brain and endocrine system? We and others have 
hypothesized that D-Asp plays a role as a neurotransmitter or neuromodulator
10, 13, 17, 53, 94, 95
. As 
discussed in previous sections, there are many studies supporting D-Asp as a transmitter. 
Meanwhile, a neuromodulator is a molecule in the nervous system that does not induce a nerve 
impulse but may modify the depolarization profile of the postsynaptic membrane in the presence 
of a neurotransmitter.  
One important point to keep in mind is that a selective receptor for D-Asp has yet to be 
identified. D-Asp is known to activate NMDA-like receptors
96
. In addition, D-Asp may work as 
neuromodulator for 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid-like receptors to 
slow receptor activation time. For example, the activation time of the squid glutamate receptor 
increased three-fold with the presence of both L-Glu and D-Asp compared with the activation 
time induced by L-Glu alone
94
. Conversely, in electrophysiological experiments on pleural and 
buccal ganglia cells of A. californica
95, 97
, some cells only responded to D-Asp, thereby 
suggesting that a D-Asp-specific receptor does exist. These experiments showed about half of the 
cells responded to both D-Asp and L-Glu to evoke an action potential, whereas the rest of the 
cells responded to either D-Asp or L-Glu alone. D’Aniello and coworkers13 have also performed 
an interesting experiment with L. vulgaris to determine whether D-Asp and L-Glu bind to the 
same receptor. Independent stimulations of D-Asp and L-Glu on L. vulgaris skin chromatophores 
indicated that the D-Asp receptor was different from the L-Glu receptor because each type of 
amino acid stimulated a specific color of skin chromatophore. The same study also showed an 
elevated level of cAMP,  a putative second messenger, in rat and L.vulgaris synaptosomes 
induced by D-Asp
13
. A similar trend was found in the cerebral ganglia of A. limacine, although L-
Asp did not induce increased cAMP levels
17
. These results support the idea that D-Asp can act as 
an intercellular signaling molecule.  
Besides acting as neurotransmitters for short-range intercellular signaling, at times cell-
to-cell signaling molecules function at longer distances. Is the same functional duality true of D-
Asp? For example, in the neuroendocrine system, D-Asp behaves like a hormone to regulate the 
reproductive system; specifically, it has been reported to be involved in steroid hormone 
synthesis in the rat pituitary gland, Leydig cells, and testis
8, 98, 99
; to increase luteinizing and 
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growth hormone release
99
 and prolactin release
100
 in rat pituitary; to decrease 
proopiomelanocortin and α-melanocyte-stimulating hormone in mouse pituitary101; to inhibit 
melatonin release
67
; and to regulate luteinizing hormone-releasing hormone, α-melanocyte-
stimulating hormone, GABA, dopamine and oxytocin in the rat hypothalamus
102, 103
. In non-
mammalian tissues, D-Asp has been found to regulate hormones in the reproductive organs of the 
frog, lizard, and ascidian
18, 20, 39
. However, many details of the D-Asp signaling pathways remain 
to be elucidated. For example, D-Asp may use cAMP and cGMP as secondary messengers to 
regulate testosterone level in testis Leydig cells and luteinizing hormone level in pituitary of rats, 
respectively
104
, while other studies report that D-Asp regulates mRNA transcription of hormones 
without affecting cAMP levels to increase testosterone in rat Leydig cells
98, 105
.  
Another interesting possibility is that D-Asp serves as a precursor of endogenous NMDA, 
which may be involved in intercellular signaling
39, 99, 100
. NMDA has been detected in rat brain 
and neuroendocrine tissues
99, 100
 and in invertebrates
39, 106-109
, although many locations with 
substantial D-Asp have little or no detectable levels of NMDA. There are cases where NMDA is 
formed from D-Asp via the enzymatic activity of D-Asp methyltransferase (or the so called 
NMDA synthetase), which transfers the methyl group of S-adenosyl- L-methionine to D-Asp for 
NMDA formation
99, 100, 109
. Considering that DAspO also digests NMDA
72, 73
, and that NMDA is 
a well-documented agonist for NMDA receptors
110
, NMDA is a key player in multiple signaling 
pathways. 
While a number of the studies described above support an intercellular signaling role for 
D-Asp, other studies suggest non-related roles. These include the demonstration that D-Asp is 
localized in the nucleoli (but not in neural processes)
111
, and the report that aluminum D-Asp 
complexes induce topological changes in supercoiled DNA
112
.  Perhaps more likely is that D-Asp, 
as many other small molecules, has multiple distinct roles. After all, just because a specific role 
for D-Asp is documented, does not preclude nor invalidate the possibility that it has a function in 
other systems as well. 
2.1.8 Physiological roles of D-Asp 
Until now, the discussion has focused on the cellular functions of D-Asp. What do these 
functions imply about an overall physiological function? Several lines of evidence support its 
role in cognitive processes. Acting as an endogenous agonist for the NMDA receptor, D-Asp 
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stimulates the NMDA receptor by binding to its L-Glu-binding site
113
. As a result, D-Asp, like D-
Ser
114, 115
, may be involved in learning and memory processes as well as NMDA receptor-related 
diseases
41
. Using both genetic and pharmacological animal models, increasing the levels of D-
Asp enhanced long-term potentiation in mice hippocampal slices
116
. Chronic D-Asp elevation 
also reduced cortical-striatal long-term depression and attenuated pharmacologically induced 
schizophrenia-like symptoms
117
. In addition, oral administration of D-Asp improved the spatial 
learning and memory ability of treated rats when compared with control rats. Moreover, 
randomized rats possessing higher endogenous D-Asp levels in the hippocampus take less time to 
complete tasks (Fig 2.4)
118
. In a recent study, D-Asp was shown to rescue the hippocampal age-
related synaptic plasticity deterioration in mice, implying an intriguing possibility that it can 
counteract the age-related reduction of NMDA receptor signaling
119
. Reduced D-Asp levels were 
found in human brain samples from patients with Alzheimer’s disease compared to normal 
brains
120
. Although the mechanism of how D-Asp exerts its activity at the neuronal level is still 
poorly understood, this set of research certainly supports the possibility that D-Asp plays a major 
role in the neuronal mechanisms underlying learning and memory.  
Because abnormal functioning of the NMDA receptor has been implicated in various 
neuronal diseases, studies have been carried out to elucidate the relationship between 
endogenous D-Asp levels and the pathophysiological processes of NMDA-related diseases, such 
as Alzheimer’s. The differences in D-Asp concentration between normal and Alzheimer human 
brains were first described in 1991, where D-Asp occurred at less than half the concentration of 
normal levels in the white matter of Alzheimer brains
6
. In another study of Alzheimer’s disease 
in the human brain, D-Asp decreased in three neocortical regions, as well as the subcortical 
hippocampus and amygdala, but not in the cerebellum, an area which lacks the neuropathological 
changes of Alzheimer’s120. 
2.2 Other D-amino acids in the nervous system 
 Besides D-Asp, there are several additional D-amino acids found in the nervous system of 
animals. In this section, details of endogenous D-Ser, D-Ala, and D-Glu are highlighted. 
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2.2.1  D-Serine  
2.2.1.1 D-Ser distribution 
 D-Ser is the most extensively studied D-amino acid in mammalian brain for which its 
localization, biosynthesis and degradation pathways, storage in neuronal cells, release upon 
stimulation, receptor on neuron surface, physiological role and pathological implications have 
been found (see Table 2.1), and there are good review articles
121-127
. In rodent and human brain, 
high amount of D-Ser is contained in specific tissues such as cerebral cortex, hippocampus, and 
striatum
128-130
 while CNS of invertebrate also have tissues with high D-Ser content, like cerebral 
ganglia of Aplysia californica
56
. At cellular level, D-Ser is found more in astrocytes, a type of 
glia cells, rather than neurons
131
 thus some metabolic pathways of D-Ser mainly occur in glia 
cells. Temporal change of D-Ser concentration is also reported in rodent and human brain
128, 131, 
132
. In the case of rat brain studies, D-Ser concentration of the whole brain is substantial level at 
birth but, in the following development stages, different parts of the brain showed various 
profiles of D-Ser concentration change
2, 132
. For example, D-Ser concentration in cerebellum 
increases within the first postnatal week, keep high concentration for a few days, and then the 
concentration rapidly decreases due to increased DAAO level
131, 132
.   
2.2.1.2 D-Ser metabolism 
 The metabolic pathways of D-Ser have been also studied well. Endogenous D-Ser is made 
by enzymatic activity of serine racemase that converts L-Ser into D-isomer
133
 while D-Ser is 
oxidatively degraded by DAAO
134, 135
. So it is no wonder that distribution of D-Ser has 
relationship with serine racemase and DAAO distributions; high amount of D-Ser is co-localized 
with where high amount of serine racemase is expressed and low amount of DAAO presents
133, 
134
. Once D-Ser is produced, it is stored in glia vesicles
136
 that are responsible for D-Ser 
production by membrane-bound serine racemase, D-Ser transportation, and D-Ser uptake by 
vesicular D-Ser transporter
137
. The stored D-Ser is kept until glia cells are stimulated to release 
the content of glia vesicles. Upon stimulating glia cells, D-Ser is released to extracellular space 
through exocytosis of the vesicles
138
. At extracellular space, D-Ser is quickly degraded by 
DAAO
135
 or taken up from extracellular space to glia cells
139
.  
 
 
  31 
2.2.1.3 D-Ser roles at molecular, cellular, and physiological levels 
 The released D-Ser from glia cells into extracellular space works as a signaling molecule. 
NMDA receptor, an important group of cell surface receptors for excitatory neurotransmission 
and brain functions like learning and memory
140
, uses D-Ser to modify its activity
141-143
. When D-
Ser is introduced to the surface of neurons with NMDA receptors, the current evoked by NMDA 
receptor is potentiated
135
. Interestingly, D-Ser binds to glycine-binding site of NMDA receptor
144
 
where glycine was considered to bind as a main co-agonist of NMDA receptor but D-Ser  is more 
potent
145, 146
. In fact, D-Ser distribution resembles to NMDA distribution so that high amount of 
D-Ser is available where large number of NMDA receptors are found
131
. Considering D-Ser 
influence on NMDA receptors and the fact that D-Ser is found more in glia cells, D-Ser is 
considered as a gliotransmitter
136
. Thus, D-Ser is considered to play an important role on 
cognitive activities such as learning and memory through modifying the function of NMDA 
receptor
114, 115
. This physiological effect is most likely due to long-term potentiation of synaptic 
transmission
147, 148
 but may be caused by other mean like long-term synaptic depression
149
. On 
the other hand, too high or too low concentration of D-Ser results in undesired (de)activation of 
NMDA receptors to induce various neurodegenerative diseases such as schizophrenia
122
, 
epilepsy
150
, and amyotrophic lateral sclerosis
151
. Since D-Ser is closely related these diseases, 
NMDA receptor site for D-Ser and D-Ser metabolic pathways can be a target for disease 
treatment, like in the case of schizophrenia treatment
122
.   
2.2.2  D-Alanine 
 D-alanine (Ala) has been found in various animals such as mollusks
152-155
, crustaceans
156-
158
, and mammals
159-161
 including human
6
. While a relatively high concentration of D-Ala is 
found in some organs, D-Ala concentration is relatively low in the CNS and brain; in mammals, 
an exception is in the anterior pituitary gland
156, 158, 161
. In these tissues, D-Ala metabolism 
appears to be regulated by two enzymes: Ala racemase for D-Ala biosynthesis and DAAO for D-
Ala degradation. Looking at invertebrates, a study on crayfish shows that Ala racemase is PLP-
dependent enzyme
162
 and, even more, cDNA clone has been isolated from prawn with conserved 
amino acid sequence for PLP-binding site
163
 although isolated mammalian Ala racemase has not 
been reported yet. The racemase can convert L-Ala into D-Ala and vice versa
162, 164, 165
 so, in 
general, conversion from L- to D-Ala is more favorable to result in net D-Ala production. For D-
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Ala regulation, DAAO oxidize D-Ala to keep appropriate amount in tissues. In mutant mouse and 
rat brains with lacking DAAO activity, significantly higher amount has been observed in all 
regions of brain
160, 166, 167
. On the other hand, the physiological role(s) of D-Ala in CNS is not 
clearly established while D-Ala in non-nervous system seems to be an important factor for 
marine animals to adjust their salinity tolerance
156, 157, 164
. In mammalian nervous system, D-Ala 
may regulate blood glucose level because that D-Ala is reported to be localized specifically in 
cells that are key players of blood glucose control, namely adrenocorticotropic hormone-
secreting cells in anterior pituitary gland
168
 and insulin-secreting beta-cells in pancreas
169
. It has 
been also reported that D-Ala concentration in rat anterior pituitary changes with circadian 
rhythm
170
 while D-Ala concentration increases in gray matter of human brain with Alzheimer's 
disease
6
. Considering these reports, it is possible that D-Ala is an important factor for controlling 
activity level of animals by regulating blood glucose level but excess amount may cause 
pathological state of brain. 
2.2.3 D-Glutamate 
 D-Glu is an enigmatic endogenous amino acid with some reports that gives D-Glu 
presence in nervous system or brain of animals: nervous system of crustaceans
171
, brains of 
fishes
172, 173
, amphibians
173
, avians
173, 174
, and mammals
175, 176
. Kera et. al. has reported that D-Glu 
amount in brain of rat is independent of gender while D-Glu amount in kidney and liver of male 
rat is higher than that of female rat
175
, suggesting that DAspO activity is correlated to the amount 
of D-Glu detected in these tissues
175, 177
. Thus, DAspO is considered to be a major enzyme that 
regulates D-Glu digestion. On the other hand, metabolic origin of D-Glu in animals has not been 
reported yet. D-Glu uptake to some specific cells in mouse brain has been shown
178
, indicating 
that only specific type(s) of cells have efficient cellular setup for D-Glu uptake. This specific 
uptake may results in D-Glu use as signaling molecule in brain. However, endogenous D-Glu 
biosynthesis in animals has not been reported yet although bacterial D-Glu racemases are well-
characterized
179-181
, therefore a large portion of D-Glu metabolism in animals remains to be 
elucidated. 
2.3 Conclusions 
The research field of endogenous D-amino acid is still young and rapidly growing. 
Although D-Ser has been studied extensively for its molecular and cellular perspectives to 
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establish its role as a gliatransmitter, the other D-amino acids are remained for further 
investigation to clarify these aspects. The last decade has been an exciting time for D-Asp 
research while the research on D-Ala and D-Glu are still in slow progress probably due to their 
low abundance and technical difficulty for measurements. As rapid progress of D-Asp research 
tells much about its formation and degradation, more detail is required on biochemical and 
cellular data to fully describe D-Asp metabolism and function(s). 
Many of the cited studies highlight the existence, localization, formation and release of D-
Asp in neurons in a surprisingly wide range of animals. Recent results include data 
demonstrating that D-Asp fulfills many requirements for it to be considered as a neurotransmitter, 
a hypothesis that has been proposed by several
10, 13, 17, 53, 95
. Of course, while the studies 
involving mammalian tissues are exceedingly relevant and well performed, they have not 
completely addressed one required facet for a molecule to be considered a transmitter. The 
formation and/or uptake, transport to terminals, and activity-dependent release must all occur in 
the exact same neuron, something only demonstrated for the larger and more accessible 
invertebrate neurons to date. Exciting work by the Snyder group
55
 has also shown that D-Asp has 
a trophic role (Fig 2.2a, b), which is perhaps not surprising given its presence during 
embryogenesis. Data on how D-Asp performs one or both roles are still needed. Of course, 
another well-known transmitter, serotonin, is known to have both transmitter and trophic roles 
182
. 
Therefore, we will not be surprised if D-Asp is also found to have multiple distinct functions 
within the brain.  
Perhaps more intriguing is the recent speculation of a correlation between D-Asp and 
several mental disorders such as Alzheimer’s disease and schizophrenia10, 41. Although 
preliminary work has been done
117, 120, 183, 184
, further investigations are required to confirm these 
reports and demonstrate whether modifying D-Asp formation, release or degradation can impact 
the progression of such diseases. In the case of D-Ser, many research groups are actively 
studying on physiological and pathological meanings of D-Ser. These efforts are not limited to 
finding the relationship between a certain disease and endogenous D-Ser amount but also looking 
for possible treatment methods of these diseases by controlling D-Ser metabolic pathways. The 
future is bright for uncovering the function of these exciting but enigmatic molecules. 
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2.5 Tables and figures 
 
 
Figure 2.1. D-Asp has been characterized via multiple measurement approaches. (a) 
Immunoreactivity measurement via a D-Asp antibody provides cellular localization, with the 
immunoreactivity against D-Asp observed in the anterior lobe (AL) and posterior lobe (PL), but 
not in the intermediate lobe (IL) in 6-week-old rat brain. Scale bar, 140 µm. (b) Chiral HPLC has 
been used for D-Asp characterization, with the D-Asp identified via its removal via D-aspartate 
oxidase (DAspO) digestion from Aplysia limacine cerebral ganglia neurons. Separation 
condition; C-18 column (0.45 cm×25 cm) was eluted at 1.2 mL/min, with programmed gradient 
consisting of solution A (5% acetonitrile in 30 mM citrate/phosphate buffer, pH 5.6) and solution 
B (90% acetonitrile in water).  (c) Chiral capillary electrophoresis works with nanoliter volume 
assays and so has enabled subcellular analysis, in this case from an individual Aplysia sensory 
neuron. *, unidentified peaks Separation condition: 21 kV normal polarity was applied to an 
uncoated fused-silica capillary (65–75 cm, 50 µm i.d./360 µm o.d.) filled with separation  
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solution consisting of 20 mM β-cyclodextrin, 50 mom sodium dodecyl sulfate in 50 mM borate 
buffer (pH 9.4) and 15% methanol (V/V). Panel a from 
29
, used with permission from Elsevier; 
panel b from 
17
 is adapted with permission, copyright © 2006 from John Wiley and Sons; and 
panel c from 
44
 is reprinted with permission from Miao, H.; Rubakhin, S. S.; Sweedler, J. V., 
Anal. Chem. 2005, 77. 7190-7194. Copyright 2005 American Chemical Society.  
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Figure 2.2. Asp racemase distribution and its trophic effect. Mouse Asp racemase was 
expressed in adult hippocampus and (a) the racemase expression was locally suppressed by 
short-hairpin RNA (shRNA) against the racemase (shRNA-DR) in newborn neurons (green 
fluorescence) while control shRNA did not suppress the racemase expression in newborn 
neurons (red fluorescence); hippocampus cells (blue) were stained with 4',6-diamidino-2-
phenylindole. Scale bar, 50 µm. (b) Survival rate of newborn neurons is compared with shRNA-
DR treatment vs. shRNA-control treatment. Neurons contain both shRNA-DR and control 
shRNA expressed yellow fluorescence. *, P <.05; n = 4 mice for each time point, ANOVA. (c) 
Immunohistochemical measurement of an Asp racemase in the cerebral ganglion from Aplysia 
capable of racemizing both D-Asp and D-Ser. The C- and F-cluster neurons are indicated by the 
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area enclosed in the dotted line. (d) CE analysis on C- and F-cluster neurons showed high 
amounts of D-Asp and D-Ser. Separation condition: 27 kV normal polarity was applied to an 
uncoated fused-silica capillary (80cm total length, 70 cm effective length, 75 µm i.d./360 µm 
o.d.) filled with separation buffer. The separation buffer for Asp enantiomers consisted of 40 
mM β-cyclodextrin and 60 mM sodium deoxycholate in 200 mM borate buffer, pH 9.5.  The Ser 
enantiomer separation buffer consisted of 10 mM γ-cyclodextrin and 50 mM sodium dodecyl 
sulfate in 75 mM borate buffer, pH 10.5. Panels a and b from 
55
 are used with permission from 
Kim, P. M.; Duan, X.; Huang, A. S.; Liu, C. Y.; Ming, G. L.; Song, H. J.; Snyder, S. H., Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107. 3175-3179, copyright 2010 National Academy of Sciences, 
U.S.A.; panels c and d from 
56
 are used with permission, © the American Society for 
Biochemistry and Molecular Biology.  
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Figure 2.3. D-Asp release and co-localization within synaptic vesicles. Extracellular D-Asp 
concentrations (a) before and (b) after potassium ion stimulation that induced D-Asp release 
from cerebral ganglia of Aplysia californica. In (a) and (b), the black trace (original) is the 
electropherogram of the original sample and the red trace (spiked) is the electropherogram of the 
sample spiked with 1 µM D-Asp, Arrows indicate the increase in D-Asp signal due to the 
addition of 1 µM standard D-Asp and the change due to potassium ion stimulation (labeled 
standard and stimulation, respectively). Co-localization of D-Asp and secretory granules in PC12 
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cells under immunofluorescent microscopic observation of (c) chromogranin A, a marker of 
secretory granules and (d) D-Asp; (e) merged images of c and d. Scale bar, 10 µm. Higher D-Asp 
content was observed in synaptic vesicles than in other cell regions in (f) rat Rattus norvegicus 
and (g) squid Loligo vulgaris. Panels a and b from 
53
 are used with permission, © 2010 by John 
Wiley & Sons, Inc.; panels c–e from 92 are used with permission, © the American Society for 
Biochemistry and Molecular Biology; and panels f and g are based on the data table in 
13
. 
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Figure 2.4. Improved spatial learning and memory in rats treated with D-Asp. (a) 12 rats 
treated with 40 mM sodium D-Asp and 12 rats treated with 40 mM NaCl (control) were trained 
in the Morris water maze to measure latency in reaching the platform hidden in the maze. After 
the acquisition phase, the platform position was changed before starting the reversal phase, while 
the other settings were the same. (b) Relationship between the endogenous D-Asp in 120-day old 
rat hippocampus and the time to reach the platform in the Morris water maze system of the 
corresponding rats that were trained in the Morris water maze system.  Figure is adapted from 
118
 
and used with permission, Springer Science+Business Media. 
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Features Characteristics Reference 
Spatial Distribution  
in Brain 
High concentration in frontal cortex, hippocampus, 
and striatum of adult rodents and human 128-130
 
Temporal  
Distribution 
High concentration in prenatal and early postnatal 
brain of rodents and human 128, 131, 132 
Biosynthesis Serine racemase in astrocytes 
133, 134
 
Receptor NR1 subunit of NMDA receptor 
141-146
 
Degradation D-amino acid oxidase 
134, 135
 
Cellular/Physiological 
Functions 
Increasing long-term potentiation, effect on 
learning and memory 144-148
 
Related Diseases 
Schizophrenia, epilepsy, amyotrophic lateral 
sclerosis, Alzheimer’s disease 122, 150, 151 
 
Table 2.1.  Summary of endogenous D-Ser properties.  
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Chapter 3 
 
Characterization of a Novel Amino Acid Racemase in the 
Aplysia californica Central Nervous System 
 
 
This chapter is adapted from “A Novel Pyridoxal 5’-Phosphate-dependent Amino Acid 
Racemase in the Aplysia californica Central Nervous System” by Liping Wang, Nobutoshi Ota, 
Elena V. Romanova, and Jonathan V. Sweedler that was published in Journal of Biological 
Chemistry, 2011, 286 (15): p. 13765-13774, DOI: 10.1074/jbc.M110.178228
1
.   
 This project was initiated by Liping Wang who performed bioinformatics to select 
appropriate putative D-Asp proteins, isolated RNA of the novel amino acid racemase, performed 
cDNA cloning, and obtained the corresponding amino acid racemase (DAR1) through bacterial 
purification and purification. I worked on characterization of DAR1 function and determined 
enzyme kinetics. These studies used a chiral separation of NDA-derivatized aspartate, serine, 
glutamate, and alanine enantiomeric pairs by CE-LIF. Co-localization of DAR1 and its D-amino 
acid products was checked through two independent experiments; Liping Wang and Elena 
Romanova carried out whole-mount immunohistochemistry that showed distribution of DAR1 
within Aplysia central nervous system (CNS) while I worked on quantitative analysis of D-amino 
acid products in Aplysia CNS samples prepared by Elena Romanova. The manuscript was 
written by all coauthors. This project was supported by Award No. NS031609 from the NINDS, 
National Institutes of Health, and by Award Nos. CHE-04-00768 and CHE-05-26692 from the 
National Science Foundation (NSF).  
 The authors thank Dr. Gary Olsen (UIUC) for bioinformatics consultation, Peter Yau 
(UIUC) for protein purification advice, and Dr. Leonid Moroz (University of Florida) for 
discussions concerning the nascent A. californica genome, the University of Illinois Roy J. 
Carver Biotechnology Center for oligo synthesis, DNA sequencing, and antibody production, 
and the University of Illinois Beckman Institute Imaging Technology Group for fluorescence 
imaging assistance.  
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3.1 Introduction 
D-Serine (D-Ser) and D-aspartate (D-Asp) are endogenous molecules with known or 
putative cell-to-cell signaling activities in the CNS. D-Ser is predominantly found in forebrain 
structures
2
, and acts as a co-agonist of the NMDA receptor, regulating activity at its glycine 
modulation site
3
. Converted from L-serine (L-Ser) by the pyridoxal 5’-phosphate (PLP)2-
dependent serine racemase (SerR) in astrocytes
4
, D-Ser can be degraded by D-amino acid oxidase 
(DAO)
5
 and acts as a novel glial neurotransmitter/neuromodulator
6, 7
. Abnormal levels of SerR 
and DAO have been observed in schizophrenia patients
8-10
, suggesting a connection between D-
Ser levels and brain function, including mental illness.  
In contrast to D-Ser, D-Asp is widely distributed in animals. It has been found in the brain, 
retina, and endocrine and exocrine tissues of both vertebrates and invertebrates
11
. D-Asp displays 
a temporal pattern during animal development, beginning with transient high levels between 
embryonic and early postnatal stages, and rapidly declining to trace levels in most tissues in 
young adults
5, 12
. Interestingly however, as animals mature, D-Asp is found at increasing levels in 
endocrine tissues
13
. The enzyme required for the biosynthesis of D-Asp in the brain was not 
identified until recently, when the first mammalian aspartate racemase, DR, was cloned and 
characterized
14
, although, how much this enzyme accounts for overall D-Asp synthesis is unclear. 
While the mechanism by which D-Asp forms remains under investigation, its catabolism is well 
understood and occurs through the enzyme D-aspartate oxidase
15, 16
. 
Efforts to understand D-Asp function are also ongoing. Indirect evidence points to 
hormonal roles
11
, whereas other studies have shown its involvement in vision
17
, embryonic 
development
18, 19
, learning and memory
20
, and neurogenesis
14
. Several groups, including ours, 
have proposed that D-Asp can act as a neurotransmitter
13, 21-23
. Further research is required to 
elucidate the physiological role of this intriguing signaling molecule.  
Clearly, many questions remain about D-Asp formation, regulation and ultimately, its 
function; uncovering the answers will require having knowledge of enzymatic D-Asp 
biosynthesis. Although the D-Ser biosynthesis pathway was described in 1999
4
, as noted, DR, the 
first D-Asp racemase enzyme from the animal brain, was just recently reported
14
. DR converts L-
Asp to D-Asp, and its knockdown reduces newborn neuron survival and dendritic arborization in 
adult mouse hippocampus. In invertebrates, significant quantities of D-Asp are also found in 
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nervous and endocrine tissues, indicating a potentially conserved D-Asp signaling pathway 
among Metazoan. However, the origin of the D-Asp in these tissues has not been clarified, nor 
has a DR-like enzyme been reported in A. californica. So far, the only invertebrate Asp racemase 
described, SbAspR, was isolated from the foot muscle of the bivalve Scapharca broughtonii
24
. 
But it is unknown if the enzyme is also present in bivalve nervous and endocrine systems. In a 
prior study
25
, we detected high levels of D-Asp (%d/l + d) in the F-, C-, and G-clusters of the 
cerebral ganglion of the A. californica CNS, with the highest D-Asp content (85%) found in the 
insulin-producing F-cluster cells. We also observed enzyme activity in the cerebral ganglion that 
could transfer [
14
C] from L-Asp to D-Asp in radioisotope pulse-and-chase experiments. 
In this report, we describe the cloning of an Asp racemase gene, dar1, from the A. 
californica CNS, the characterization of a DAR1 protein by enzyme assay, and examination of 
CNS enzyme localization. Racemase assays were performed using small-volume capillary 
electrophoresis (CE) with laser-induced fluorescence (LIF) detection, selected because the 
methodology is well suited for separating chiral amino acids from small-volume samples
26, 27
. 
We characterized the enzyme activity and show that DAR1 converts L-Asp to D-Asp, and vice 
versa, with a much smaller Km for L-Asp substrate than for D-Asp substrate. The enzyme also 
exhibits Ser racemase activity with a similar Km for both L-Ser and D-Ser substrates. The 
distribution of DAR1 in A. californica indicates it is found in tissues previously shown to have 
significant levels of D-Asp. Based on this dual racemase activity, the same tissues have been 
characterized for D-Ser, and both D-Ser and D-Asp are shown to co-localize. 
3.2 Experimental procedures 
3.2.1 Animals 
Adult A. californica (125–250 g) were purchased from the Aplysia Research Facility in 
Miami, FL. Animals were kept in an aquarium of artificial sea water (460 mM NaCl, 10 mM 
KCl, 10 mM CaCl2, 22 mM MgCl2, 6 mM MgSO4, and 10 mM HEPES, pH 7.8) with constant 
aeration at 14–15 °C and were used within 2 weeks of arrival. For dissection, animals were 
anesthetized with an intraperitoneal injection of MgCl2 solution (390 mM) at 30–50% of body 
weight (v/w), and the interconnected CNS ganglia removed with surgical tools. The ganglia were 
either immediately processed for RNA isolation, total protein extraction or amino acid extraction; 
or treated with 1% protease Type IX (Sigma-Aldrich) in artificial sea water containing 100 
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units/ml penicillin G, 100 µg/ml streptomycin, and 100 µg/ml gentamicin for 1 h at 34 °C to aid 
in the removal of connective tissues prior to CNS immunohistochemistry staining. 
3.2.2 CE-LIF instrumentation and sample analysis 
Separations were performed using an automated P/ACE MDQ CE system equipped with 
LIF detection (Beckman Coulter). The CE system was coupled to an external diode laser 
56ICS426 (Melles Griot) emitting 440 ± 8 nm, with the coupling performed via a fiber optic 
cable (OZ Optics). The laser power was adjusted to 3 milliwatt at the output terminus of the optic 
cable to avoid damage to the photomultiplier tube (PMT). A bandpass filter of 490 ± 15 nm 
(Omega Optical), located prior to the PMT, selects the appropriate fluorescence emission band 
for detection. For separations, uncoated fused-silica capillaries (Polymicro Technologies) were 
used. Capillaries were injected with 0.1 M NaOH at a pressure of 30 psi for 1 min and allowed to 
be primed in NaOH for 25 min before their initial use. Samples were introduced into the 
capillaries by pressure injection of 0.5 psi for 5 s. The separation buffer for the Asp and 
glutamate (Glu) enantiomers contained 200 mM borate, pH 9.5, with 60 mM sodium 
deoxycholate (SDC) and 40 mM β-cyclodextrin (β-CD)28. The Ser enantiomer separation buffer 
contained 75 mM borate, pH 10.5, with 50 mM SDS and 10 mM γ-cyclodextrin29. For chiral 
alanine (Ala) separation, the inlet buffer consisted of 25 mM phosphate, pH 2.2, containing 4% 
(w/v) sulfated β -CD, and the outlet buffer of 50 mM phosphate, pH 2.230. For Asp, Glu, and Ser 
chiral separations, capillaries of 75 µm inner diameter (ID) and 360 µm outer diameter (OD) 
were used. Capillary total length was 80 cm with an effective length of 70 cm to the detection 
window. Separations were carried out by applying 27 kV of normal polarity. Between two runs, 
the capillaries were rinsed with methanol (30 psi, 0.5 min), 0.1 M NaOH (30 psi, 1 min), and 
separation buffer (30 psi, 1 min). For Ala enantiomer separations, capillaries of 50 µm ID and 
360 µm OD were used with 60 cm total length and 50 cm effective length. A reverse polarity of 
20 kV was applied for separations. After each run, the capillaries were rinsed first with methanol 
(30 psi, 0.5 min), followed by the inlet separation buffer (30 psi, 1 min). CE-LIF results were 
displayed as electropherograms, which show analyte peak fluorescence intensities against 
analyte migration time from the capillary injection site to detection window. For quantitative 
analysis, the peak areas of amino acid analytes and internal control glycine from the CE 
electropherograms were obtained using Origin 8 software (Origin Lab Corp.). To obtain analyte 
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concentrations, analyte peak areas were divided by glycine peak areas to generate normalized 
analyte peak area values, and converted to concentrations using working curves generated with 
known concentrations under the same experimental conditions. 
3.2.3 DAR1 racemase assay 
Chemicals and reagents for the enzyme assays were of the highest grade available and 
purchased from Sigma-Aldrich unless specified otherwise. Naphthalene-2,3-dicarboxaldehyde 
(NDA) was purchased from Invitrogen. Water was deionized and purified using a Barnstead E-
PURE purification system (ThermoFisher Scientific) and sterilized by passing through 0.22 µm 
filters. Procedures were performed at room temperature unless otherwise noted. The racemase 
assays contained a cofactor mix composed of 20 µM PLP, 4 mM ATP, 2 mM DTT, and 2 mM 
MgCl2 in Tris-HCl buffer of various concentrations and pH depending on the specific 
experiment. To perform each assay, L/D-Asp, L/D-Ser, L-Glu, or L-Ala (2.5–200 mM) substrates 
were incubated with 1–10 µg of purified DAR1 in 100–150 µl Tris-HCl buffer (25–50 mM, pH 
7.0–8.5) and cofactor mix at 30 °C for 2–4 h. Negative controls contained heat-inactivated 
enzyme or no substrates. At the end of the incubation period, glycine (3–5 mM) was added to 
each reaction and used as an internal control for subsequent sample treatments and analyses. 
Enzyme was removed by either TCA precipitation or the alternative filtration method described 
below, before amino acid derivatization for CE analysis. To remove the enzyme, 5% cold TCA 
was added to the reaction samples and incubated for 10 min on ice followed by centrifugation at 
10,000 g for 10 min. TCA was then removed from the samples by two extractions with equal 
volume of water/saturated ether. Enzyme can also be removed from an assay sample by 
centrifugation in a Pierce® Concentrator 7 ml/9K molecular-weight cutoff (ThermoFisher 
Scientific) for 5 min to collect protein-free filtrate. Protein-free samples were diluted in 50 mM 
borate buffer, pH 9.4, to appropriate volumes so that amino acids were derivatized with an 8  
excess of NDA and 20  excess of potassium cyanide (KCN) in 50 mM borate buffer, pH 9.4, for 
45 min. The reaction was stopped by diluting 1:10 with 50mM borate buffer, pH 8.5, and 
immediately frozen on dry ice. Samples were then subjected to CE-LIF analysis within 24 h. 
3.2.4 Enzyme kinetics assay 
A series of concentrations (2.5–80 mM) of Ser or Asp substrates were incubated with 1–2 
µg of purified enzyme in 100-µl reactions in 50 mM Tris-HCl buffer, pH 8.5, for Ser reactions, 
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or pH 8.0 for Asp reactions, containing cofactor mix at 30 °C for 70–150 min. At the end of the 
incubations, 5 mM glycine was added to each reaction as an internal control. In addition, L-Ala 
was added to the Ser samples and L-Glu was added to the Asp samples so that the total amino 
acid concentrations in all reactions were equal to the highest substrate concentrations. The 
enzymes were immediately removed by centrifugal filtration as described above. The protein-
free samples were then diluted to appropriate concentrations with 50 mM borate buffer, pH 9.4, 
so that 800 µM of the total amino acids were derivatized with 6.4mM NDA and 16 mM KCN in 
a 10-µl reaction for 60 min. The reactions were stopped by 1:10 dilution with 50 mM borate 
buffer, pH 8.5, and quickly frozen on dry ice until CE-LIF analysis. The quantity of amino acid 
products was calculated from the linear function produced by a standard amino acid calibration 
curve by co-assaying standard amino acids without enzyme with samples containing enzyme. 
The enzyme catalysis velocity is defined as a µmol product formed by 1 mg of enzyme during a 
1 h reaction time at 30 °C under the described assay conditions. The inverse enzyme velocities 
were plotted against inverse substrate concentrations and fitted to a linear model using Microsoft 
Excel to generate Lineweaver-Burk Plots. The Km and Vmax values were calculated from the 
inverse x- and y-intercepts of the plots. 
3.2.5 Detection of D-Asp and D-Ser in Aplysia CNS ganglion clusters 
A. californica cerebral ganglion clusters were dissected from anesthetized animals and 
immediately placed into 100–200 µl of 0.1 N HCl. The cells were homogenized manually with a 
glass homogenizer followed by sonication for 15 min in a waterbath sonicator. The materials 
were then centrifuged at 10,000 g for 10 min at 4 °C and the supernatants dried down in a 
microcentrifuge under vacuum. The dried materials were reconstituted with 10 µl of 100 mM 
borate buffer, pH 9.4. Samples (0.5 µl) were then derivatized with 1µl of 20 mM NDA and 1µl 
of 20 mM KCN for 1 h. The derivatized samples were diluted 5–20 fold with 75 mM borate 
buffer, pH 10.5, for Ser separation, or 200 mM borate buffer, pH 9.5, for Asp separation. The 
diluted samples were injected into capillary by pressure at 0.5 psi for 5 s and separated under 27 
kV with normal polarity. 
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3.3 Results 
3.3.1  DAR1 racemase activity and characterization 
We examined DAR1 PLP-dependent racemase activity toward L/D-Asp, L/D-Ser, L-Glu, 
and L-Ala substrates, and observed enzyme behaviors under different temperatures and buffer pH 
levels, and the effects of ATP/MgCl2 on the enzyme activity. These measurements were 
accomplished with CE-LIF, an approach well suited for chiral amino acid separation and 
detection. Our assay results demonstrated that DAR1 was active toward both Asp and Ser 
substrates and converted these chiral enantiomers in both directions (Fig. 3.1). However, DAR1 
had no detectable activity when 10 µg of purified enzyme was incubated with 100 mM L-Glu or 
100 mM L-Ala (D-Glu and D-Ala were not tested) in a 150 µl reaction containing 50 mM Tris-
HCl, pH 8.0, with cofactors at 30 °C for 3 h, a condition where Asp and Ser conversion were 
easily observed. DAR1, like other PLP-dependent racemases, requires the cofactor PLP for its 
activity. Purified enzyme appeared greenish yellow and absorbed light at 420 nm, a characteristic 
of PLP-bound enzyme
31
. The absorption peak disappeared after the enzyme was incubated for 10 
min at room temperature with 2 µM aminooxyacetic acid (AOAA), a PLP-inactivating reagent 
(data not shown). The enzyme did not lose color after a 48 h dialysis, indicating a high affinity 
between the enzyme and PLP. AOAA inhibited the conversion by DAR1 of D-Ser and D-Asp 
from their corresponding enantiomer (Fig. 3.2A). The thermal stability profile of DAR1 is shown 
in Fig. 3.2B. The enzyme activity increased between 14–45 °C and started to decrease at 50 °C 
for both the Ser and Asp conversions. We examined the modulating effects of ATP and MgCl2 
on DAR1 racemase activity (Fig. 3.2C). MgCl2 (2 mM) had only a small effect on enzyme 
racemase activity but ATP (4 mM) significantly increased enzyme activity. When both effectors 
were present, the enzyme showed the largest activity for the D-Asp and D-Ser conversions. The 
ATP and MgCl2 concentrations were not optimized for DAR1; we chose the concentrations 
based on published research on Ser and Asp racemases
32, 33
. Finally, Fig. 3.2D depicts the pH-
dependent DAR1 activity. The enzyme showed little racemase activity below pH 6.5 (data not 
shown) and an increasing activity between pH 7.0–8.5 in 50 mM Tris-HCl buffer. 
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3.3.2 Enzyme kinetics 
The DAR1 Asp and Ser racemase kinetics linear curves are shown in Lineweaver-Burk Plots 
(Fig. 3.3). Analyzing the linear fits, the Km (mM) was determined to be 8 ± 2 (S.D.) for L-Asp, 94 
± 30 for D-Asp, and 15 ± 4 and 16 ± 2 for L-Ser and D-Ser, respectively; the Vmax (µmol h
-1
 mg
-1
) 
for the same substrate order was determined to be 3.3 ± 0.8, 7.9 ± 1, 11 ± 1.6, and 15 ± 3, 
respectively. 
3.3.3 Co-localization of DAR1 and D-amino acids in the A. californica CNS 
We raised a rabbit polyclonal antibody against DAR1 and used it to perform whole-mount 
(versus section) immunohistochemistry with A. californica CNS material. We stained the 
isolated CNS, including the buccal, pleural, pedal, abdominal, and cerebral ganglia, and their 
connective and peripherally extending nerves. The immunohistochemistry experiments revealed 
a highly localized distribution of DAR1 protein in the CNS (Fig. 3.4). The antibody exclusively 
stained F-, C-, G-, and B-cluster cells located in the middle region of the fused cerebral ganglia. 
The staining was specific; controls without primary or secondary antibody produced only 
background signal (data not shown). The other ganglia showed only background staining, except 
for a group of 3–4 unidentifiable neurons in the vicinity of B1 and B2 landmark neurons in the 
buccal hemiganglia and a lone neuron in the abdominal hemiganglia. 
Whereas our prior research characterized D-Asp, we had not performed D-Ser separations; 
the optimum CE conditions are distinct for the two amino acid pairs. Thus, we have re-measured 
both D/L-Asp and D/L-Ser within several CNS structures. As demonstrated in the CE-LIF 
electropherograms in Fig. 3.5, not only was a high level of D-Asp (more than L-Asp) once again 
detected, a significant amount of D-Ser (less than L-Ser) was also found for the first time in the 
F/C-clusters. 
3.4 Discussion 
 We have characterized a novel racemase enzyme from A. californica. Homology data 
suggest that the known mammalian and our new molluskan amino acid racemase share a 
conserved structural similarity. Intriguingly, although a similar enzyme has not been found in 
mammals, a distinct aspartate racemase (DR) was recently identified
14
. DR has less than 20% 
identity to the other five racemase proteins, and it lacks the similar PLP binding and stabilizing 
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sequences shared by other racemase groups. Based on our phylogenetic analysis, Ser racemases 
are closer to serine dehydratase (EC 4.3.1.17), while DR is closer to glutamate-oxaloacetate 
transaminase enzyme (EC 2.6.1.1). It appears that DAR1 and DR are distinct Asp racemases 
from animal brains. Intriguingly, DAR1 and mammalian SerR are closely related and yet the 
mammalian DR is distinct. Are there other animal amino acid racemases that are still unknown? 
Given recent reports of high levels of D-Glu
34
 and D-Ala
35
 in rat brain, this appears a certainty. It 
will be interesting to determine their structures and how they fit within the growing Metazoan 
CNS amino acid racemase family. After expressing and purifying DAR1, we tested its activity 
and ability for racemizing the amino acids that have previously been shown to be present at high 
levels in animal brains: Asp, Ser, Glu, and Ala
36, 37
. The enzyme was active toward Ser and Asp 
enantiomers but showed no activity toward Glu and Ala. To our best knowledge, DAR1 is the 
first characterized eukaryotic racemase that can catalyze the racemization of two substrates. The 
enzyme is PLP-dependent and appears to require dimerization for activity. Homodimers have 
been observed with mouse SerR and SbAspR
32, 38, 39
. The recombinant DAR1 appears to be heat-
tolerant under the assay conditions used. As with most protein enzymes, its activity increases 
with increasing temperatures. The enzyme shows a wide temperature range of activity, between 
14 and 45 °C. We examined ATP and MgCl2 effects on DAR1 racemase activity and found that 
both reagents, especially ATP, are important for promoting enzyme racemase activity, and they 
act more effectively together than they do alone, as shown in Fig. 3.2C. It has been proposed that 
ATP and MgCl2 exert allosteric regulatory effects on mouse SerR by lowering enzyme Km
32
. 
Although not examined, the same regulatory mechanisms might be at work for DAR1. Studies 
by other groups have also shown that other nucleotides and bivalent cations could regulate 
animal Asp and Ser racemase activities. As examples, besides Mg
2+
, both Ca
2+
 and Mn
2+
 have 
been shown to promote mouse SerR activity
32
 and AMP promoted SbAspR activity, but ATP 
reduced it
33
. It is interesting that while ATP has a positive effect on DAR1 activity, the same 
nucleotide showed an inhibitory effect on SbAspR activity. The opposite effects of ATP on the 
two closely related mollusk aspartate racemases indicate that the enzymes may have different 
physiological functions. In addition, SbAspR might have a role in energy metabolism under 
anoxic conditions in bivalve muscle tissues
33
.  
The enzyme is more active under alkaline conditions. Both Ser and Asp activities were 
low below pH 6.5, while increasing between pH 7.0 and pH 8.5 in 50 mM Tris-HCl. The pH 
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profile is similar to that of a mouse SerR
4
 and distinct from that reported for SbAspR
24
, where 
the enzyme activity started to decrease above pH 8.5. We found that the optimal buffers were 25 
mM Tris-HCl, pH 8.5, for L-Asp conversion and 50 mM Tris-HCl, pH 9.0, for L-Ser conversion 
(data not shown), suggesting that ion strength and pH can affect enzyme efficiency for a 
particular substrate. We chose 50 mM Tris-HCl, pH 8.5, for most of our assays to simplify the 
experimental procedures.  
We determined the Km and Vmax for the four racemase reactions catalyzed by DAR1 (Fig. 
3.3). The kinetic data revealed the following. First, the enzyme favored L-Asp over D-Asp, the 
smaller the Km, the higher affinity a substrate has for an enzyme, and the Km for L-Asp substrate 
was about 10  smaller than that for D-Asp substrate. Although the enzyme had twice as large a 
Vmax for L-Asp production, L-Asp is 10  more competitive than D-Asp for binding to the enzyme. 
Therefore, the enzyme was more efficient in producing D-Asp from L-Asp than vice versa. 
Differing from the Asp kinetics, Ser kinetics are comparable with both substrates. But the Km 
values for both forms of Ser were still 4  larger than that for L-Asp. Based on the Km values, the 
enzyme had the highest affinity toward L-Asp, followed by L-Ser/D-Ser, and then D-Asp. 
However, more studies are required to understand the physiological meaning of these kinetics 
parameters.  
The selected presence and relatively sparse distribution of DAR1 within the A. 
californica CNS, specifically several cerebral ganglion clusters and isolated single neurons in the 
buccal and abdominal ganglia, suggests that the enzyme serves a specific function within these 
areas (and does not have a more general "cellular housekeeping" role). At this point, we have 
determined that DAR1 is capable of synthesizing D-Asp and it is localized to specific structures. 
Using CE-LIF we measured the presence of D-Ser and D-Asp in the cells containing the enzyme 
to determine if they co-localize. It is particularly telling that the enzyme was present in the F-, C-, 
and G-clusters where high levels of D-Asp content were previously reported
22, 25
; we now 
confirm the co-localization of D-Ser and D-Asp in these structures. The correlation of DAR1 and 
its products supports our determination that the enzyme is involved in the actual biosynthesis of 
D-Asp and D-Ser. Several years ago, we hypothesized that D-Asp was a neurotransmitter in the A. 
californica CNS
25
. Since then, we have accumulated evidence of D-Asp release from and uptake 
by the cerebral ganglia. The finding of a D-Asp biosynthesizing enzyme in the cerebral ganglia 
substantiates this hypothesis. 
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3.5 Conclusion 
We have isolated a novel racemase from A. californica neuronal tissues, characterized its 
biochemical features, and validated its ability to form D-Asp and D-Ser. DAR1 can catalyze 
racemization reactions between Asp and Ser enantiomers with differing kinetics. The enzyme Km 
and Vmax values suggest a substrate preference order of L-Asp > L-Ser ≥ D-Ser > D-Asp. DAR1 is 
the first Asp and Ser racemase discovered in an invertebrate brain and the first eukaryotic dual 
Asp/Ser racemase described. Using whole-mount CNS tissue staining with DAR1 antibody, we 
localized DAR1 to the central region of the cerebral ganglia where the F- and C-clusters are 
situated. These clusters contained a high level of D-Asp and a significant amount of D-Ser. The 
co-localization of the enzyme with the four amino acids demonstrates that DAR1 plays a role in 
the biosynthesis of D-Asp and/or D-Ser in the F/C-clusters. Future work will examine the roles of 
D-Asp and D-Ser in cell-to-cell communication and study the interactions between these two 
putative signaling molecules. 
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3.7 Tables and figures 
 
Figure 3.1. DAR1 Asp and Ser racemase activities. CE-LIF electropherograms of enzyme 
reactions with four substrates (A) L-Asp, (B) D-Asp, (C) L-Ser, and (D) D-Ser. L-Asp/ D-Asp (80 
mM), or L-Ser/ D-Ser (10 mM), were incubated with 1 µg of enzyme and cofactors in a 150-µl 
reaction buffer of 50 mM Tris-HCl, pH 8.0 (Asp reactions), or in 25 mM Tris-HCl, pH 9.0 (Ser 
reactions), at 30 °C for 2.5 h. A substrate starting concentration of 12 µM L-Asp, 4 µM D-Asp, 
20 µM L-Ser, or 20 µM D-Ser was injected into the capillary. Migration time: time for analytes 
moving from the capillary injection site to detection window. 
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Figure 3.2. DAR1 racemase activity characterization. A, AOAA inhibition assay: L-Asp (50 
mM) and L-Ser (20 mM) were each incubated with 1 mM AOAA, 4 µg of DAR1 and cofactors 
in a 150-µl reaction containing 25 mM Tris-HCl, pH 8.5, at 30 °C for 2 h. The substrate starting 
concentration of 100 µM L-Asp or 40 µM L-Ser was injected into the CE capillary. B, thermal 
stability of DAR1 racemase activity: L-Asp (80mM) and L-Ser (50mM) were each incubated 
with 1 µg of DAR1 and cofactors in a 100-µl reaction in 50 mM Tris-HCl, pH 8.5, at 14, 30, 37, 
45, and 50 °C for 3 h (Asp) or 1 h (Ser). The substrate starting concentration (100 µM for L-Ser 
or 160 µM for L-Asp) was injected into the capillary. C, effects of ATP and MgCl2 on DAR1 
racemase activity: L-Ser (20 mM) and L-Asp (200 mM) were each incubated with 2 µg each of 
DAR1, PLP, and DTT with either 4 mM ATP or 2 mM MgCl2 or both effectors, in a 100-µl 
reaction in 50 mM Tris-HCl, pH 8.5, at 30 °C for 1 h. The substrate starting concentration (40 
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µM L-Ser or 100 µM L-Asp) was injected into the capillary. Controls with heat-inactivated 
enzymes were subtracted from the data shown. For panels A–C, the data from three batches of 
enzymes were averaged and the standard deviations represented by error bars. D, pH dependence 
of DAR1 racemase activity: CE-LIF electropherograms of a DAR1 racemase reaction with L-
Asp (top 4 panels) or L-Ser (lower 4 panels) substrate. L-Ser (13.3 mM) and L-Asp (26.7 mM) 
were each incubated with 1 µg of DAR1 and cofactors in a 150-µl reaction in 50 mM Tris-HCl, 
at pH 7, 7.5, 8.0, and 8.5 at 30 °C for 3 h. The substrate starting concentration of 1.77 µM L-Ser 
or 17.7 µM L-Asp was injected into the capillary. 
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Figure 3.3. Lineweaver-Burk plots of DAR1 racemase kinetics. Racemase assay with various 
concentrations of Asp or Ser substrates were performed and the conversion products quantified 
as described in the Experimental Procedures. Inverse reaction velocities were plotted against 
corresponding inverse substrate concentrations and fitted to produce the Lineweaver-Burk plots 
for (A) Asp and (B) Ser substrates. 
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Figure 3.4. DAR1-like immunoreactivity localization in the A. californica CNS. A, whole-
mount staining of the CNS (except abdominal ganglia) with rabbit anti-DAR1 serum shown as a 
rhodamine fluorescence micrograph; BG: buccal ganglia; CG: cerebral ganglia; PdG: pedal 
ganglia; PlG: pleural ganglia. B, light micrograph of desheathed but not stained CG control; 
enlarged CG staining image from (A) showing (C) a rhodamine fluorescence micrograph and (D) 
a bright-field fluorescence micrograph. 
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Figure 3.5. CE-LIF electropherograms of D-Asp and D-Ser in CNS neuronal F/C clusters. A. 
californica cerebral ganglion F/C cluster neurons were dissected and subjected to amino acid 
separation with CE-LIF using optimal buffer for (A) Asp separation and (B) Ser separation. 
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Chapter 4 
 
Correlation between Circadian Rhythm and L-Glutamate 
Quantity in Suprachiasmatic Nucleus of Mouse Brain 
 
 
This chapter is adapted from “Signals from the brain sleep-wake system regulate behavioral 
timing via the circadian clock” by Sabra M. Abbott, Jennifer M. Arnold, Qing Chang, Hai Miao, 
Nobutoshi Ota, Christine Cecala, Paul E. Gold, Jonathan V. Sweedler, Martha U. Gillette that 
has been submitted to PLoSOne in 2013. This work was supported by grants from the United 
States National Institutes of Health to S.M.A. (GM07143 and NS47802), P.E.G. (AG07648 and 
DA024129), J.V.S. (P30 DA018310), and M.U.G. (HL092571Z and HL086870), and the 
National Science Foundation to J.V.S. (CHE- 1111705) and P.E.G. (08-43175 and 10-52464). 
Funding agencies had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript.  
 This project was collaborative work of the research groups of Martha Gillette, Paul Gold, 
and Jonathan Sweedler at University of Illinois at Urbana-Champaign. Animal surgery and 
treatment, behavioral analyses, and statistical analyses were conducted by Gillette group. In the 
Sweedler research group, Hai Miao and I had worked on quantitation of L-glutamate in collected 
mouse suprachiasmatic nucleus samples provided by Gillette group by utilizing CE-LIF while 
Christine Cecala measured serotonin. In the following sections, my CE-LIF measurements on L-
glutamate are highlighted; the background, measurements of acetylcholine and serotonin and 
behavioral studies from others on this team are included in an abbreviated form to allow the 
complete story to be highlighted. 
4.1 Introduction  
 Glutamate is a non-essential amino acid and its L-isomer is a critical excitatory 
neurotransmitter that is used for nearly all excitatory neurons in the central nervous system
1
. 
There are multiple receptors for glutamate including AMPA, kainate, and NMDA receptors
2-4
; 
glutamate is estimated to be released in more than half of all brain synapses
1
. Therefore, the 
amount of glutamate release is an important parameter to measure because it has large influence 
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on neuronal activity and firing. One physiological aspect influenced by glutamate is sleep-wake 
cycle
5-8
 that has gained attention and has studied for decades. 
 Why are sleep-wake cycles important? Sleep and wakefulness are highly regulated 
behavioral states that globally modulate brain and body functions. These daily alternations in 
state are determined by interactions between homeostatic and circadian brain systems
9, 10
, whose 
orchestrated action is prerequisite to good health
11
. The daily sleep-wake cycle emerges from 
integration of homeostatic sleep need, which is determined by the duration of time spent awake 
and asleep, and a circadian timing system that regulates the propensity for wakefulness with a 
near-24-hour rhythm. The rhythmic variation in sleep propensity observed during a period of 
sleep deprivation is predicted to derive from this
12
.  
 Outputs from the suprachiasmatic nucleus (SCN) transmit time-of-day information that 
generates circadian oscillations in the functional state and physiology of brain stem regions that 
control sleep and waking
13, 14
. A potential substrate of interface between homeostatic and 
circadian systems may be pathways to the SCN originating in the brainstem
15, 16
 from nuclei with 
identified roles in sleep and arousal
15, 17, 18
.  
Within the brainstem, the laterodorsal tegmental (LDTg) and pedunculopontine tegmental 
(PPTg) nuclei are two regions of a cell group of established importance for regulating sleep and 
wake states
19
. Their projections to other parts of the brain have been demonstrated to contain 
both acetylcholine (ACh) and glutamate
20
, neurotransmitters that modulate sleep and 
wakefulness
21, 22
. ACh and glutamate also regulate phasing of circadian rhythms through their 
action at the SCN
23-26
. This suggests that afferent pathways from these regions to the SCN may 
transmit information regarding the vigilance state of the animal and that glutamate could mediate 
this communication.  
 We examined the hypothesis that signals from brain regions that control homeostatic 
sleep engage the circadian system. Despite anatomical evidence for neural projections 
connecting LDTg and PPTg neurons of the homeostatic brain stem with the SCN
15
, the 
neurochemical identity and functional context of this potential feedback loop have not been 
evaluated. To test for functional communication, we stimulated discrete pontine sites in the 
mouse brain and measured two responses: changes at the SCN in levels of neurotransmitters 
from LDTg and PPTg neurons
15
 that are stimulus-dependent, and changes in the phasing of 
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behavioral circadian rhythms. Depending upon stimulus conditions, ACh and/or glutamate levels 
were augmented in SCN. Equivalent stimulations of the median raphe nucleus (MRN) had no 
effect of ACh or glutamate levels in SCN, but increased SCN serotonin (5-HT). When effects of 
PPTg stimulation on behavioral circadian rhythms were assessed across the circadian cycle of 
animals in constant environments, settings that caused glutamate release at the SCN produced 
significant shifts in behavioral rhythms, similar to those seen with direct glutamatergic 
stimulation of SCN brain slices
27
 or in vivo
24
. Injection of glutamate into the PPTg in early 
subjective night also induced circadian delays, suggesting effects are due to local PPTg 
activation
28
. Our data provide evidence for complex neurochemical communication with 
behavioral consequences between brain regions controlling homeostatic sleep states and 
circadian rhythms. These findings suggest that alterations in homeostatic sleep state can by these 
pathways feed back upon the circadian system to reset the SCN time-base, thereby realigning 
circadian and homeostatic systems.  
4.2 Experimental procedures  
4.2.1 Animals 
Male C57BL/6J mice were obtained at 5 weeks of age from Jackson Laboratories (Bar Harbor, 
ME). Animals were housed and cared for as described in animal protocols in full compliance 
with NIH guidelines for the humane care and treatment of animals, approved by IACUC and 
supervised by the Division of Animal Resources at the University of Illinois at Urbana-
Champaign.  
4.2.2 Surgical procedures 
Surgeries on mice were performed ≥ 1 week after animals arrived (18-23 g). Mice were 
anesthetized with sodium pentobarbital (80 mg/kg i.p.). A microdialysis guide (CMA/7; 
CMA/Microdialysis; North Chelmsford, MA) was implanted in the SCN, and a bipolar 
stimulating electrode (MS303/1; Plastics One, Inc.; Roanoke, VA) was implanted into the LDTg, 
PPTg, or MRN using a stereotaxic apparatus (Stoelting; Wood Dale, IL). Coordinates based on 
bregma were: SCN, -0.1 mm AP, -0.1 mm ML, -4.0 mm DV; LDTg, -5.2 mm AP, -0.5 mm ML, 
-3.3 mm DV; PPTg, -4.3 mm AP, -1.8 mm ML, -3.7 mm DV; MRN, -3.8 mm AP, 0.0 ML, -4.8 
DV. DV measurements were made from the dural surface, and coordinates were determined 
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experimentally with the aid of a mouse brain atlas
29
. Cannulae were secured with small machine 
screws (0-80 x 1/16; Plastics One, Inc.; Roanoke, VA) and cranioplastic cement (Plastics One, 
Inc.; Roanoke, VA).  
4.2.3 Housing 
Mice were housed individually in cages (30 x 17 x 22 cm) equipped with running wheels (14.5 
cm dia.) that were placed inside ventilated light-tight wooden boxes (171 x 41 x 34 cm). Wheels 
were locked on the first day to minimize novel wheel-induced phase shifts, which can increase 
the time necessary for entrainment. For light-dark cycles, lights were kept at 100 lux for 12 h, 
followed by 12 h of darkness, regulated by computer. Up to 6 mice could be housed in each box. 
For experimental procedures, animals were placed in light-tight circadian activity monitoring 
systems (CAMS) and maintained in darkness under constant conditions
30
.  
4.2.4 Glutamate measurements 
4.2.4.1 Microdialysis 
For microdialysis procedures, animals were gently restrained, a microdialysis probe (CMA/7; 
CMA/Microdialysis; North Chelmsford, MA) was inserted into the dialysis guide aimed at the 
SCN and was attached to the animal using a head-block tether system (Harvard Apparatus; 
Holliston, MA). Connecting cables for stimulation (305-305 TT2; Plastics One, Inc.; Roanoke, 
VA) also were attached at this time. Animals were placed into a CAMS designated for 
stimulation experiments, where they were attached to fluid (Instech; Harvard Apparatus; 
Holliston, MA) and electronic swivels (Plastics One, Inc.; Roanoke, VA). Placing animals in 
CAMS for the duration of the experiment allowed experiments to be performed on a freely-
behaving, undisturbed animal, under controlled environmental conditions.  
Before each experiment, the microdialysis probe was placed in a standard solution containing 
ACh (20 nM) and choline (20 nM) for 20 min to determine the recovery rate of the probe. When 
implanted in SCN, the probe was continuously perfused at a rate of 1 µl/min with artificial 
cerebral spinal fluid (aCSF; 0.13 M NaCl, 4 mM KCl, 0.75 mM NaH2PO4 (anhydrous), 2 mM 
Na2HPO4, 1 mM dextrose, 2 mM MgCl2, 1.7 mM CaCl2) containing 500 nm neostigmine, a 
cholinesterase inhibitor. Animals were allowed to equilibrate for at least 1 h before samples were 
collected. For experiments performed during the animal’s dark period, the microdialysis probe 
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was attached during the light period and animals were perfused with aCSF until 2 h before the 
first collection, at which point the perfusion fluid was switched to aCSF containing 500 nM 
neostigmine. This allowed all probes to be attached during the light period, while standardizing 
the length of time each animal was exposed to neostigmine. After ~1 h for equilibration, baseline 
samples were collected every 20 min for 1 h. Animals were then stimulated, and microdialysis 
sample collection continued every 20 min for an additional 100 min. Samples were split for 
analysis of either ACh or glutamate content, and kept at -80 °C until analysis.  
4.2.4.2 Capillary electrophoresis/laser-induced fluorescence (CE-LIF)  
Several CE-LIF systems with different characteristics were used to quantify the 
glutamate and 5-HT samples
31
. A part of glutamate measurements was done with the previously 
reported method and instrumentation
32
. Here the glutamate approaches via CE-LIF are described. 
Most of the several hundred glutamate samples from the SCN after stimulation to the median 
raphe (as shown in Figure 3) were measured by the following method and instrumentation. 
Glutamate was analyzed by derivatizing 1 µl of microdialysis sample with 0.5 µl of 16 µM 
fluorescein (as an internal standard), 0.5 µl of 4 µM L-cysteic acid, 0.5 µl of 10 mM naphthalene-
2,3-dicarboxaldehyde (NDA) in methanol, and 0.5 µl of 20 mM KCN. Fluorescein, L-cysteic 
acid, and KCN were dissolved in 100 mM borate buffer (pH 9.5). The mixture of the sample and 
the derivatization reagents was allowed for 45 minutes to complete the reaction in dark at room 
temperature. After the derivatization, the mixture was diluted by adding 17 µl of 100 mM borate 
buffer (pH 8.7). An automated CE system, P/ACE MDQ with LIF detector (Beckman Coulter, 
Fullerton, CA), and 75-µm I.D./360-µm O.D. fused-silica capillary (Polymicro Technologies, 
Phoenix, AZ) was used. A diode laser emitting 442 ± 7 nm (CVI Melles Griot, Carlsbad, CA) 
was used as the excitation source for LIF. Fluorescence signal was selected by a band-pass filter 
of 490 ± 15 nm (Omega Optical, Brattleboro, VT) and was set before a photomultiplier tube of 
the LIF detector. The separation buffer consisted of 100 mM borate, 30 mM sodium 
deoxycholate, and 20 mM β-cyclodextrin at pH 8.7. The sample was injected by pressure of 0.5 
psi for 5.0 sec and was separated by 27 kV normal polarity. For quantitative analysis, the peak 
areas of amino acid analytes and internal control fluorescein from the CE electropherograms 
were obtained using Origin 8 software (Origin Lab Corp.). To obtain relative concentrations of 
glutamate for all samples, glutamate peak area was divided by fluorescein peak area to generate 
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normalized glutamate peak area values, and converted to concentrations using working curves 
generated with known concentrations under the same experimental conditions.  
4.2.5 Circadian wheel-running behavior 
 For analyzing circadian state in mice, animals were individually housed in cages 
equipped with a running wheel. A magnet (neodinium grade-27; Magnetic Energies, Inc.; San 
Antonio, TX) was attached to each wheel, and each revolution of the wheel moved it past a 
hermetically sealed reed switch (HSR-067RT; Hermetic Switch, Inc.; Chickasha, OK), closing a 
circuit (Tischkau et al., 2000). This circuit closure was transmitted to a computer running 
Clocklab Acquisition software (Actimetrics, Inc.; Evanston, IL). Data were stored in 6-min bins, 
and the resulting rhythm was plotted in an actogram and analyzed with Clocklab Analysis 
software (Actimetrics, Inc.; Evanston, IL).  
Because of the need to include neostigmine in the perfusion fluid for microdialysis 
experiments, which could interfere with the circadian behavior of the animal, microdialysis 
experiments were performed separately from behavioral experiments. Animals were entrained to 
a 12-h L:12-h D cycle for at least 10 days following surgery, and then were released to constant 
darkness (DD). Following at least 10 days in DD, treatment times were calculated as described 
previously (Tischkau et al., 2000). For stimulation experiments, 5 min before the predicted 
treatment time, the subject was removed under dim (<1 lux) red light, gently restrained, and a 
connecting cable (305-305 TT2(C); Plastics One; Roanoke, VA) was attached to the previously 
implanted electrode. The subject was returned to its home cage, and placed in one of two CAMS 
designated for stimulations. The connecting cable was attached to an electronic swivel (SL2C; 
Plastics One; Roanoke, VA) and the animal was stimulated (Grass SD9 Stimulator; Grass 
Product Group; West Warwick, RI) at the calculated CT of treatment. Control animals were 
attached to the connecting cable/swivel for 20 min, but no current was passed through the 
stimulator. Immediately following stimulation, the control subject was unhooked from the 
connecting cable and returned to home housing.  
4.2.6 Histology 
Following experiments, animals were sacrificed and brains were frozen on dry ice. Brains then 
were sliced into 40 µm sections using a cryostat, and stained with cresyl violet to determine the 
placement of the microdialysis probe within the SCN, or with cholinesterase staining to verify 
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the placement of the stimulating electrodes within the LDTg, PPTg, and MRN using standard 
procedures
33
.  
4.2.7 Statistics 
Data were analyzed with either one-way analysis of variance (ANOVA) with Tukey post hoc 
comparison, or by Student’s t-test, using SigmaStat analysis software.  
4.3 Results  
 For quantitative analysis of glutamate, CE-LIF conditions were carefully optimized. 
Given multiple SCN dialysate samples, CE separation conditions were modified so that no 
interference peaks overlapped glutamate peak. For quantitation of glutamate peak areas, 400 nM 
of fluorescein was used as an internal standard; this was added into every dialysate sample. 
Meanwhile, 400 nM of L-cysteic acid were also mixed to dialysate samples to monitor if NDA 
derivatization was performed successfully.  Due to several hundreds of dialysate samples for 
glutamate measurement, the separation was designed to finish in relatively short time with 
sufficient peak resolutions for glutamate and fluorescein (Fig 4.1). When glutamate peak was 
unexpectedly high or broad, another separation condition (200 mM borate, 60 mM sodium 
deoxycholate, and 40 mM β-cyclodextrin at pH 9.5) that had higher separation capability with 
slower analyte migration was used to confirm the peak ratio of glutamate and fluorescein. The 
obtained data set of glutamate quantitation was used with the data sets of the other chemical 
measurements and the study on mouse behavior for further interpretation. 
 To investigate neurochemical communication between homeostatic and circadian 
regulatory centers, we measured neurotransmitter release in the SCN following stimulation of the 
LDTg or PPTg. Both direct and indirect cholinergic projections from these pontine nuclei 
innervate the SCN in nocturnal
15, 16
 and diurnal
34
 rodents. Therefore, we stimulated the LDTg or 
PPTg of freely-behaving mice on a 12hr:12hr light-dark schedule, while collecting 
microdialysate from the SCN for analysis. 
 To evaluate whether stimulation of the LDTg vs. PPTg results in differential 
neurotransmitter release, animals received LDTg and/or PPTg stimulation (150 µA, 10 Hz, 2-
msec pulse duration) at 15 h after lights-on, Zeitgeber Time (ZT) 15 and each releasate sample 
was analyzed for both ACh and glutamate. Whereas projections from the LDTg and PPTg to the 
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SCN have been characterized as cholinergic
15
, these regions comprise mixed populations of 
neurons with distinct stimulus-release characteristics. Results indicate that, as before, ACh levels 
at the SCN increase significantly following LDTg stimulation (Fig. 4.2A, 325 ± 60%, p < 0.001, 
ANOVA) and glutamate levels also increase significantly (157 ± 44%, p < 0.001, ANOVA).  
 Three stimulus conditions were used for the PPTg: 1) 150 µA, 10 Hz, 2-msec pulse 
duration applied continuously for 20 min, as in previous experiments; 2) 40 µA, 0.2 Hz, 0.2-
msec pulse duration continuously for 20 min; and 3) 400 µA, 60 Hz, 0.2-msec pulse duration 
applied as a 1-sec train every min for 20 minutes. Conditions 2 and 3 have been shown 
previously to favor glutamate or ACh release, respectively, from these neurons
35, 36
. We found 
that Condition 1 increases ACh release significantly at the SCN (188 ± 39%, p = 0.01, ANOVA), 
while there is a non-significant trend towards an increase in glutamate (136 ± 14%, p = 0.105, 
ANOVA, Fig. 4.2B). Condition 2 causes a significant increase in glutamate at the SCN (201 ± 
13%, p < 0.05, ANOVA) without significantly affecting ACh (118 ± 9%, p = 0.213, ANOVA, 
Fig. 4.2C). Condition 3, on the other hand, significantly increases ACh (194 ± 34%, p<0.01, 
ANOVA) without affecting glutamate (91 ± 6%, p = 0.827, ANOVA, Fig. 4.2D). These findings 
suggest that the population of PPTg neurons that cause neurotransmitter release at the SCN may 
vary depending upon the context in which neurons are activated.  
 To evaluate whether neurotransmitter release at the SCN is specific to the brain region 
stimulated, we evaluated the response to stimulating the serotonergic median raphe nucleus 
(MRN), which does not synthesize ACh or glutamate. We analyzed SCN dialysate for serotonin 
(5-HT), as well as for ACh and glutamate. Stimulation of the median raphe significantly 
increases 5-HT at the SCN (Condition 3, 364 ± 89%, p < 0.05, ANOVA), as anticipated. None of 
the stimulus conditions tested increased ACh or glutamate levels (Fig. 4.3).  
 We wished to determine whether these neurochemical signals from the brainstem engage 
the circadian timekeeping mechanism in the SCN; thus, the effects on phasing of wheel-running 
activity were evaluated by stimulating LDTg and PPTg of mice with stimulation of 150 µA, 10 
Hz, 2-msec pulse duration in constant dark environments. LDTg stimulated at circadian time (CT) 
14 and 15 showed a significant delay in locomotor rhythms while the rhythms were advanced by 
stimuli at CT 24/0. PPTg also showed significant delays in circadian activity rhythms by 
stimulation only at CT 15, while not significant, PPTg stimulations during the subjective daytime 
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trended toward delays in activity. Also, to determine whether the SCN undergoes circadian 
changes in sensitivity to these neurotransmitters, animals received PPTg stimulation using the 
three conditions described above at CT 6, 15, 20 or 24/0. Phasing of wheel-running onset after 
daytime stimulation, while not significantly different, showed a trend toward greater delays 
following Condition 1. In early subjective night, significant delays were seen following 
conditions 1 and 2 (p < 0.05, Student’s t-test), which increased glutamate and ACh or only 
glutamate, respectively. Phasing of behavioral rhythms was not altered following Condition 3, 
which increased ACh only.  Combining these mouse-activity studies and the neurochemical 
analysis shown above together, it has been shown that activation of mesopontine tegmental 
nuclei that results in increased glutamate at the SCN significantly changes the phasing of wheel-
running behaviors, an effect gated over the circadian cycle by clock state.  
4.4 Discussion  
 Quantitative measurement of glutamate in SCN dialysate was successfully performed 
with CE-LIF. Adding an internal standard of constant concentration into dialysate samples, 
quantitation errors associated with intra- and inter-day measurements were taken care of. The 
obtained quantitative glutamate information was utilized to find the relationship between 
glutamate amount and the related brain regions by combining the results obtained by the entire 
team to investigate some aspects of wake-sleep cycle. 
 Our data provide evidence for functional communication between brain stem nuclei with 
established roles in regulating homeostatic sleep and the circadian clock in the SCN. Stimulation 
of the LDTg or PPTg of the C57BL/6J mouse causes stimulus-specific increases in ACh and/or 
glutamate at the SCN. In addition to altering neurotransmitter levels, activation of the LDTg or 
PPTg can induce functional changes in circadian behavior. The delays in phasing of behavioral 
rhythms in response to stimulation during the early subjective night are similar to those caused 
by direct glutamatergic stimulation of the SCN in vitro and in vivo
24, 27
.  
 LDTg and PPTg both contain mixed populations of neurons
37
. Cholinergic and 
glutamatergic fibers project directly from brainstem to SCN, and also innervate intermediate 
cholinergic sites in basal forebrain. Both ACh and glutamate appear in SCN dialysate, depending 
upon the stimulus applied to brain stem sites. Glutamate levels increase in response to either 
LDTg or PPTg stimulation, although not to the same degree as ACh. While some stimulus 
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conditions alter SCN levels of both neurotransmitters, it was possible to affect glutamate without 
increasing ACh and vice versa. This suggests that a mixed population of neurons projects from 
the PPTg to the SCN. While there is evidence for direct projections from brain stem, cholinergic 
neurons of the basal forebrain also project to SCN. These forebrain projections have been 
reported to participate in circadian regulation of cognitive functions, such as selective attention, 
where they induce phase-advances in daytime
38
. Thus, while it is possible that our observed 
effects are the consequence of a relay that projects to the SCN, behavioral outcomes are more 
consistent with direct projections from brain stem.  
 Circadian behavioral responses to PPTg stimulation are varied and reflect the 
neurotransmitter profile released at SCN. Intra-SCN injection of a glutamatergic agonist in the 
early night produces delays
24
, while ACh produces advances
23
. Until now, however, the 
circadian response to the presence of both neurotransmitters simultaneously had not been 
examined. Two outcomes are possible: 1) the circadian response to the release of both 
neurotransmitters could be additive, so that the response to a delaying signal from glutamate and 
an advancing signal from ACh results in little or no net resetting, or 2) the circadian response 
could be hierarchical, with the response depending on the temporal sequence of activation or 
which signal is dominant, due to the relative efficacy of downstream signaling elements. In the 
latter cases, the net result may not differ from that stimulated by one or the other of the 
neurotransmitters alone. Our results indicate that stimulation settings that cause an increase in 
ACh without glutamate produce little or no net resetting, while glutamate produces a response of 
comparable direction and magnitude to that observed if both ACh and glutamate are present. 
This indicates that the glutamate signal is dominant to ACh and, when this signal is activated, the 
presence of ACh does not alter the net outcome. It is noteworthy that the presence or absence of 
ACh does not have a significant effect on the net magnitude of the glutamatergic response. In 
retinal innervation of the SCN, co-release of pituitary adenylyl cyclase-activating peptide 
(PACAP) with glutamate is neuromodulatory
39
.  
 Taken together, these studies demonstrate that signals from sleep-wake regulating 
brainstem regions to the SCN, either directly or indirectly, engage the circadian system. 
Activation of these pathways produces changes in neurotransmitter levels at the SCN and alters 
the phasing of circadian behavioral rhythms. A stimulus that resets the circadian clock may be an 
error signal reporting a mismatch with other oscillatory systems. Pontine projections to the SCN 
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originate from regions active during the sleep-wake cycle. Thus, neurotransmissions from the 
pontine brain stem to the SCN at specific points in the day-night cycle may be interpreted as an 
error regarding the state of the sleep/wake system in the context of time of day. Large bouts of 
sleep at abnormal times, as would be observed following sleep deprivation, might contribute to 
this error signal. The SCN generates output signals that inhibit locomotor activity
13, 14
, so 
resetting the circadian clock after a period of sleep deprivation could decrease locomotor 
behavior, a state permissive for sleep and facilitating efficient recovery of sleep lost.  
 While there is substantial evidence that sleep need and time-of-day are important 
determinants of vigilance state, support for the notion that these processes interact functionally 
has been limited
40, 41
. Animals with a functional circadian clock recover more quickly from 
periods of sleep deprivation, suggesting that an interaction between the homeostatic and the 
circadian systems provides the most efficient means of maintaining homeostasis
42
. A means by 
which this interaction might take place has been unknown. The firing rate of cells within the 
SCN is altered by sleep state
43
, evidence for bi-directional interaction between these two systems. 
The studies described here, however, are the first to demonstrate a functional relationship 
between brainstem sites that regulate sleep need and the circadian clock in the SCN. Our findings 
that activation of homeostatic sleep centers in the brainstem can cause resetting of circadian 
behavioral rhythms in a time-of-day- and state-dependent manner suggest previously 
unrecognized integration between these global brain systems, and identify new sites of potential 
vulnerability in disordered sleep.  
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4.6 Figures 
 
Figure 4.1. Typical electropherograms for glutamate measurement. A microdialysate sample 
with 400 nM fluorescein (internal standard) and L-cysteic acid (LCA, indicator of NDA 
derivatization) shown at the bottom and the sample spiked with 1 µM Glu and additional 800 nM 
fluorescein and 700 nM LCA shown at the top to confirm the peaks. 
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Figure 4.2. Depending on LDTg or PPTg stimulus conditions, glutamate or ACh increases 
at the SCN in early night. Following LDTg (A) stimulation with Condition 1 (150 μA, 10 Hz, 
2-msec pulse duration), ACh and glutamate (Glu) show a significant increase while following 
PPTg (B) stimulation ACh release is significantly increased. PPTg stimulation with Condition 2 
(C, 40 μA, 0.2 Hz, 0.2 msec pulse duration) significantly increases Glu release at the SCN. PPTg 
stimulation with Condition 3 (D, 400 μA, 60 Hz, 0.2 msec pulse duration, applied as a 1-sec train 
every min) significantly increases ACh release at the SCN. * indicates p < 0.05 by One-Way 
ANOVA with Tukey post hoc test.  
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Figure 4.3. Stimulating the MRN increases 5-HT release at the SCN, but does not affect 
ACh or glutamate levels. Stimulation of the MRN at ZT 15 with Condition 1 (A, 150 μA, 10 Hz, 
2-msec pulse duration) or Condition 2 (B, 40 μA, 0.2 Hz, 0.2-msec pulse duration), does not 
  91 
significantly increase ACh, Glu, or 5-HT levels at the SCN. However, stimulating the MRN with 
Condition 3 (C, 400 μA, 60 Hz, 0.2-msec pulse duration, applied as a 1-sec train every min/20 
min) significantly increases 5-HT release at the SCN, without affecting ACh or Glu levels. MRN, 
median raphe nucleus; 5-HT, serotonin. * indicates p < 0.05 by One-Way ANOVA with Tukey 
post-hoc test.  
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Chapter 5 
 
Analysis of D-Alanine in Islets of Langerhans of Rat 
Pancreas by Non-aqueous Capillary Electrophoresis 
 
 
This work was aimed to find out the correlation between D-alanine and peptide hormone in islets 
of Langerhans by using dissected rat pancreas.  I would like to thank Stanislav Rubakhin and 
Xiying Wang for their tremendous work on sample preparation: dissection of rats, biochemical 
tissue treatment, and isolation of the corresponding cells. Stanislav Rubakhin also provided many 
insightful suggestions for this project. 
5.1 Introduction 
 There are several D-amino acids that have been found both in the central nervous system 
and other organs such as the kidney. D-alanine (Ala) is one such D-amino acid that has been 
observed not only in microorganisms but also in various animals such as mollusks
1-4
, 
crustaceans
5-7
, and mammals
8-10
 including humans
11
. However, the physiological role of D-Ala 
has not been elucidated clearly in higher animals while its role in microorganisms and marine 
animals has been studied. In microorganisms, certain types of D-amino acids including D-Ala are 
found in cell walls
12, 13
. Thus, one possible pathway of endogenous D-Ala supply in animals is 
intestinal microorganisms
14, 15
. In marine animals, D-Ala found in tissues other than the nervous 
system seems to be an important factor in adjusting their salinity tolerance
5, 6, 16
. For regulation 
of endogenous D-Ala, two enzymes play important roles: Ala racemase for D-Ala production and 
D-amino acid oxidase (DAAO) for D-Ala degradation. Ala racemase study in crayfish shows that 
it is a PLP-dependent enzyme
17
 and its cDNA clone is isolated from prawn
18
. The racemase can 
convert L-Ala into D-Ala and vice versa
16, 17, 19
 and, in general, conversion from L- to D-Ala is 
more favorable to result in net D-Ala production due to low abundance of D-Ala compared with 
L-Ala amount. Since intestinal microorganisms produce D-Ala, it is expected that both D-Ala 
absorbed through intestinal system and D-Ala converted from L-Ala by Ala racemase contribute 
the production of endogenous D-Ala although it is not clear how much of total D-Ala amount 
each pathway accounts for. In contrast, to eliminate excess endogenous D-Ala, DAAO oxidizes 
D-Ala to keep an appropriate amount in tissues. DAAO can take several types of D-amino acids 
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and some species express DAAO subtype that prefers D-Ala as a substrate among various D-
amino acids
20-22
. This D-Ala regulation by DAAO is experimentally shown by using mutant 
mouse lacking DAAO that showed increased D-Ala in tissues and urine
14, 15, 23
. Furthermore,  
mutant mouse and rat brains which lack DAAO activity also showed a significantly higher 
amount of D-Ala in all regions of the brain
9, 24, 25
. This phenomenon may be related to a 
pathological state, for example, D-Ala concentration increases in gray matter of human brains 
with Alzheimer's disease
11
. 
 Considering studies that revealed regionally large amounts of D-Ala in some organs such 
as the pituitary gland and pancreas 
9, 10
, a physiological role of D-Ala in higher animals may be 
regulating blood glucose level because that D-Ala is reported to be localized specifically in cells 
that are key players of blood glucose control, namely adrenocorticotropic hormone-secreting 
cells in anterior pituitary gland
26
 and insulin-secreting beta-cells in the pancreas
27
. Furthermore, 
it has been reported that D-Ala concentration in rat anterior pituitary changes with circadian 
rhythm
28
. Considering these reports together, it is possible to hypothesize that D-Ala is an 
important factor for controlling activity level of animals that is mediated by changing blood 
glucose level. However, little information exists on D-Ala release. 
 This is a preliminary study where islets cells of Langerhans obtained from rat pancreas 
are used to measure the conditions required for D-Ala release. The associated challenges on this 
study are sample preparation and detection of low D-Ala signal. Sample preparation is critical to 
obtain relatively high D-Ala signal because D-Ala localization in specific types of cells are 
indicated as discussed above. Therefore, dissected tissues require further steps to provide islets 
cells. In addition, releasate collection from islets cells is desired to involve sample pre-treatment 
before instrumental analysis. Through vacuum evaporation of solvent followed by liquid-liquid 
extraction, the small amount of D-Ala released from islets cells can be detectable.   
5.2 Experimental setup 
5.2.1 Reagents and buffers 
 Ultra pure de-ionized water was prepared by Milli-Q filtration system (Millipore, 
Belford, MA). Phosphate-buffered saline (PBS) was made by dissolving 154 mM NaCl in 20 
mM phosphate buffer (pH 7.4). NaCl, Na2HPO4, and NaH2PO4 were purchased from Sigma-
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Aldrich (St. Louis, MO). Pyrophosphate buffer was made to mix appropriate amount of 
monobasic and dibasic pyrophosphate solutions to have 44 mM pyrophosphate at pH 8.0. 
Sodium pyrophosphate decahydrate and dibasic sodium pyrophosphate were purchased from 
Sigma-Aldrich. Acidified acetone was made by mixing (volume ratio) 40:6:1 acetone, water, and 
HCl (12 M). Authentic amino acids were purchased from Sigma-Aldrich and stored as solutions 
by dissolved in 100 mM borate (pH 9.5) buffer or in PBS. Naphthalene-2,3-dicarboxaldehyde 
(NDA) and potassium cyanide (KCN) were purchased from Invitrogen (Grand Island, NY). For 
non-aqueous CE separations, formamide (FA), N-methyl formamide (NMF), hydroxypropyl γ-
CD (HP-γ-CD), (1S)-(+)-camphorsulfonic acid (CS), quinine (QN), and sodium acetate are 
purchased from Sigma-Aldrich. For D-Ala peak identification, flavin adenine dinucleotide 
(FAD), D-amino acid oxidase (DAAO) from procine kidney (8.2 U/mg solid), and aqueous 
suspension of catalase from bovine liver (10000 - 40000 U/mg protein, 34 mg protein/mL 
suspension) were purchased from Sigma-Aldrich and they were dissolved in PBS. These 
solutions had 5 mM FAD, 15 U/mL DAAO and 15.6 - 62.5 U/mL catalase, respectively. 
Dichloromethane was purchased from Sigma-Aldrich for liquid-liquid extraction. 
5.2.2 Islets cell samples and islets releasate samples 
 Rat pancreas dissection and following enzyme treatment for isolation of islets of 
Langerhans were performed by Stanislav Rubakhin and Xiying Wang. Isolated islets were 
collected in PBS, pyrophosphate buffer, or acidified acetone, and the samples were stored in -
80°C freezer until they were used for NACE-LIF measurement.  
 Releasate sample was collected from isolated islets in 0.5 mL of modified Gey's balanced 
salt solution (mGBSS) in a low protein-bind tube. In each tube, 20 islets were placed and these 
islets were incubated for 30 min at 37°C with perfusion by CO2/O2 mixture. After incubation, 
400 µL of supernatant were transferred to another container to be frozen. This supernatant was 
control (or pre-stimulated) sample. Then 400 µL of 25 mM D-glucose in mGBSS were added to 
the tube containing the islets with remaining supernatant. After 30 min incubation at 37°C with 
perfusion by CO2/O2 mixture, 400 µL of the supernatant was transferred to another container to 
be frozen. This supernatant was stimulated sample. The remaining solution with islets were also 
frozen and this sample served to check if residual solution contain D-Ala which is leaked from 
the sample cells by unintentional cellular damage. 
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5.2.3 Derivatization for amino acid-samples 
 For NDA derivatization, authentic amino acid sample in PBS was mixed with equal 
amount of NDA (10 mM in methanol), KCN (20 mM in borate buffer), L-cysteic acid (5 mM in 
PBS) and L-norleucine (L-Nle, 10 µM in borate buffer) solutions. The mixture was allowed to 
react for 30 min in the dark at room temperature. Once reaction was complete, the mixture was 
diluted with fluorescein (4 µM in water) solution to obtain an appropriate concentration of N-
substituted 1-cyanobenzo isoindole (CBI)-amino acids with 2 µM fluorescein and 1 µM CBI- L-
Nle for CE measurement. Fluorescein worked as an internal standard and CBI- L-Nle worked to 
check if there was any derivatization error.  
 For cell homogenate samples, 0.5 µL sample and 0.25 µL each of NDA and KCN 
solutions are mixed with appropriate amount of 10 µM L-Nle solution in 100 mM borate, pH 9.5. 
The sample mixtrue was allowed for 30 min reaction in dart at room temperature, and then 
diluted with appropriate amount of fluorescein (4 µM in water) solution. After derivatization and 
dilution, the derivatized sample typically had 5- or 10-fold dilution of the original sample with 2 
µM fluorescein and 1 µM CBI- L-Nle. 
 Aliquots (200 µL) of releasate samples were pre-concentrated by drying into powder by 
vacuum evaporation. The dried releasate aliquots were reconstituted in 2 µL of borate buffer. In 
order to check the effect of high glucose or salt due to mGBSS in reconstituted aliquots on 
derivatization, previously published liquid-liquid extraction method with dichloromethane was 
performed. After liquid-liquid extraction, dichloromethane was evaporated in vacuum evaporator 
and aliquots were reconstituted in 2 µL of borate buffer. Once reconstituted sample with or 
without liquid-liquid extraction was prepared, the sample was mixed with NDA, KCN, L-Nle, 
and fluorescein solutions in volume ratio of 4:1:1:1:1. The derivatization mixture was allowed to 
react for 30 min in dark at room temperature and was directly used for CE analysis. The sample 
for CE analysis contained 1 µM of L-Nle and 2 µM of fluorescein.  
 For D-Ala peak identification, sample was mixed with DAAO (15 U/mL), catalase (15.6-
62.5 U/mL), FAD (5 mM) solutions, and PBS in volume ratio of 2:1:1:1:1. After 1 h incubation 
in water bath at 37°C, 1.5 µL DAAO-treated mixture were mixed with 0.5 µL of NDA solution 
and 0.5 µL of KCN solution for derivatization. The derivatization mixture was allowed to react 
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for 30 min in dark at room temperature. The derivatized sample was diluted with water or 
directly used for CE analysis. 
5.2.4 CE-LIF instrumentation and sample analysis by non-aqueous CE (NACE) 
separation 
Separations were performed using an automated P/ACE MDQ CE system equipped with 
LIF detection (Beckman Coulter). The CE system was coupled to an external diode laser 
56ICS426 (Melles Griot) emitting 440 ± 8 nm, with the coupling performed via a fiber optic 
cable (OZ Optics). The laser power was adjusted to 3 milliwatt at the output terminus of the optic 
cable to avoid damage to the photomultiplier tube (PMT). A band-pass filter of 490 ± 15 nm 
(Omega Optical), located prior to the PMT, selects the appropriate fluorescence emission band 
for detection. For separations, uncoated fused-silica capillaries (Polymicro Technologies) of 75 
µm inner diameter and 360 µm outer diameter were used. Capillary total length was 80 cm with 
an effective length of 70 cm to the detection window. Capillaries were injected with 0.1 M 
NaOH at a pressure of 30 psi for 1 min and allowed to be primed in NaOH for 25 min before 
their initial use. Samples were introduced into the capillaries by pressure injection of 0.5 psi for 5 
s. The NACE separation buffer contained 40 mM HP-γ-CD, 80 mM CS, 80 mM QN, and 10 mM 
sodium acetate in FA. Separations were carried out by applying 27 kV of normal polarity. 
Between two runs, the capillaries were rinsed with NMF (5 min), NaBH4 (5 min), 0.1 M NaOH 
(15 s), and separation buffer (1 min). The obtained electropherograms of CE-LIF were analyzed 
by using Origin 8 software (Origin Lab Corp.). For quantitative analysis, the peak areas of amino 
acid analytes and internal control fluorescein from the CE electropherograms were used. To 
obtain analyte concentrations, analyte peak area was divided by fluorescein peak area to generate 
normalized analyte peak area value, and converted to concentrations using working curves 
generated with known concentrations under the same separation conditions. 
5.3 Results 
5.3.1 Chiral separation by NACE-LIF and D-Ala peak identification 
 It is highly important to achieve baseline separation of Ala enantiomers for quantitative 
analysis because D-Ala amount is expected to be much lower than L-Ala
29
. Even though there are 
some studies reporting chiral separation of derivatized Ala enantiomers, they use sophisticated 
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liquid chromatography system
25, 30
 or CE with amine-reactive dyes other than NDA
31, 32
. NDA 
has some advantages; excitation wavelengths of NDA and NDA-derivatized analytes have large 
difference (i.e. fluorogenic dye) that results in much less interference peaks due to fluorescence 
of NDA and undesired NDA by-products, it is stable for several hours after derivatization, pH 
during derivatization results in reaction with selective analytes (e.g. pH 9.5 is optimum for amino 
acids while some peptides and proteins prefer lower pH to react with NDA
33-36
), and relatively 
short derivatization time required at ambient condition. To achieve baseline separation of Ala 
enantiomers, CE separation system was optimized. In order to develop Ala chiral separation, FA-
based separation solution showed baseline separation of Ala enantiomers while aqueous and 
other organic solvent showed only partial or no chiral resolution of Ala. Chemical additives in 
FA-based separation solution was optimized so that Ala peaks were not interfered by some major 
amino acid peaks including aspartate, glutamate, glycine, and serine as well as fluorescein and L-
Nle that worked as indicator molecules. Chiral selectors used in FA-based separation solution 
were cyclodextrin and CS. The concentration difference of these chiral selectors resulted in 
various degree of Ala chiral separation. In addition, there were several types of cyclodextrins 
used to check degree of Ala chiral separation because cyclodextrins gave diverse separation 
results based on their cavity size and functional group. Based on the optimization of separation 
buffer, chiral Ala separation was enhanced by using HP-γ-CD. For further experiments, 
separation solution consisted with 40 mM HP-γ-CD, 80 mM CS, 80 mM QN, and 10 mM 
sodium acetate in FA was used. A typical separation with this separation buffer is shown in 
Figure 5.1. 
 For D-Ala peak identification, DAAO was applied to digest D-Ala in PBS. Oxidative 
digestion of D-Ala resulted in D-Ala peak disappearance in NACE-LIF (Fig 5.2a) because the 
amino group of D-Ala was eliminated by the activity of DAAO (Fig 5.2b). It was found that 
DAAO treatment did not interfere with D-Ala derivatization or did not interfere with the D-Ala 
peak in NACE separation even with relatively high concentration of DAAO presents in 
derivatization or CE injection process (data not shown). Thus, relatively high concentration of 
DAAO, catalase, and FAD were used to speed up pre-sample treatment. For biological sample 
analysis, the samples treated with DAAO were directly derivatized with minimum dilution to 
inject highest concentration of D-Ala into CE system.  
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5.3.2 D-Ala in islets of Langerhans 
 The isolated islets of Langerhans from rat pancreas were analyzed with NACE-LIF with 
the separation buffer in the section above. One to twenty six islets were contained in each sample 
for analysis. First, islets were stored in PBS, pyrophosphate buffer, or acidified acetone solution 
to check if islets prefers to release of D-Ala into the extracellular matrix, and all samples were 
sonicated for 3 min in an ice-bath to maximize the release of D-Ala content. The obtained results 
indicated no significant difference for different islet storage solutions. Therefore PBS was 
selected for further sample storage because DAAO was dissolved in PBS, and thus, it was easier 
to predict the effect of DAAO digestion for sample in PBS rather than in different buffer.  
 In Figure 5.3, typical electropherograms of NDA-derivatized islets sample and the 
sample with DAAO treatment are shown. Even though D-Ala peak in islet sample was small, it 
was still detectable and could be eliminated by DAAO digestion. For quantitation of D-Ala, a 
quantitative working curve of y = 1.88 × 10
-3
 x was used where y is the peak ratio of D-
Ala/fluorescein and x is D-Ala concentration injected to CE in nM and limit of detection was 2.0 
nM. Given D-Ala peak intensities and the quantitation curve, average D-Ala amount per islet was 
approximately 178 ± 37 fmol (n = 6). The matrix of islet samples generally caused no 
interference on D-Ala peak. However, DAAO treatment gave interference peaks over D-Ala peak 
in some cases. This phenomenon usually is associated with evaporation of solvent within the 
incubation container during DAAO treatment for samples at 37°C. Once a large portion of 
solvent evaporates and solutes are left at the bottom of a container, some solutes in DAAO-
treated sample appeared as interference peaks in NACE-LIF measurement. Since DAAO had a 
strong yellow color under white light, it was possible that DAAO degradation due to temperature 
or lack of water causes change in its structure, leading to variation of DAAO migration. Another 
possible cause could be a changed NDA reaction with DAAO or catalase. Whichever the reason 
for the interference, it was important to minimize drying solutes in the DAAO-treated sample. 
For this reason, DAAO-treated samples were centrifuged at 30 min after the beginning of 
incubation.  
5.3.3 D-Ala in releasate of isolated islets 
 Releasate from the 20 isolated islets per container was first collected from supernatant of 
the islet sample incubated in mGBSS as control, and then collected from supernatant of the islet 
  99 
sample incubated in D-glucose. The collected supernatant was dried into powder, and then 
reconstituted in borate buffer. At this point, the effect of glucose or mGBSS on sample 
derivatization was checked by employing liquid-liquid extraction with dichloromethane. 
Through liquid-liquid extraction, ionic and hydrophilic molecules were trapped in the aqueous 
layer and hydrophobic molecules including the neutral form of CBI-amino acids were collected 
in the dichloromethane layer. The dichloromethane layer was then transferred to another 
container to collect hydrophobic molecules by evaporating dichloromethane. The remaining 
solute of releasate sample was reconstituted in 2 µL of borate buffer. This 2-µL reconstituted 
sample was used to compare the NACE-LIF result of the same 2- µL releasate samples without 
liquid-liquid extraction; both samples were 40-fold concentrated after derivatization in this 
experiment. These results showed that the pattern of migrating peaks were almost identical (data 
not shown). In terms of peak intensities, the sample with no liquid-liquid extraction showed 
slightly stronger intensities of the peaks. This small difference of peak intensities is most likely 
due to slight loss of analytes during the extraction. Since 2 µL was close to the minimum sample 
volume for confident sample injection into capillary, further experiments used no liquid-liquid 
extraction.  
 D-Ala peak identification for the releasate samples were carried out by standard CBI-D-
Ala spiking and only one out of three samples showed a D-Ala peak. In Figure 5.4, NACE-LIF 
results of releasate collected from isolated islets in mGBSS (control) and in mGBSS with D-
glucose (stimulated sample) are shown with the results of the same samples spiked with CBI-D-
Ala. These results demonstrate that D-Ala was released from islets by glucose stimulation and the 
D-Ala quantitation curve provides the D-Ala amount based on the observed D-Ala peak; the D-
Ala amount per whole releasate sample was 2.8 fmol and average D-Ala amount released per 
islet was 0.14 fmol. 
5.4 Discussion and conclusion 
 From an analytical perspective, a measurement protocol for D-Ala in islets and islet 
release has been designed. NACE separation was optimized for CBI-Ala enantiomers to measure 
quantitative values of D-Ala in islets of Langerhans dissected from rat pancreas. NACE-LIF in 
this study has shown baseline separation of Ala enantiomers while some other CBI-amino acids, 
namely aspartate, serine, and glutamate, were also baseline separated. This separation capability 
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partially is from FA as a solvent; chemical additives have different solubility in FA from the 
solubility in aqueous solution and ionic strength of FA-based solution is expected to be lower 
than aqueous solution. Therefore, FA-based CE separation can be good alternative of aqueous 
CE separation. 
 The amount of D-Ala calculated from the D-Ala peak in NACE-LIF measurements 
showed 178 ± 37 fmol D-Ala per islet. Assuming that islet is spherical shape and the diameter of 
islet is about 0.1 mm
37-39
, D-Ala concentration per islet is roughly 290 µM. Given the density of 
islets is close to 1.1 g/mL
40
, the estimated D-Ala amount is approximately 310 nmol/g islet. 
Comparing with the previous studies reporting the D-Ala amount measured for rat pancreas (29.2 
± 5.0 nmol/g wet tissue
10
 and approximately 7.5 - 35 nmol/g wet tissue obtained in different time 
of a day
28
), D-Ala concentration in islets is higher than the other regions of pancreas. Higher D-
Ala concentration in islets indicates that D-Ala is localized to islets of Langerhans and this 
matches the published results indicated by immunohistochemical studies
27
. Combining the 
reported result that D-Ala and insulin are co-localized in beta cells of islets
27
  and the fact that 
insulin release is promoted by increased glucose level, the detectable amount of D-Ala release 
from islets by D-glucose stimulation might mean that D-Ala works as a signaling molecule 
related to feeding; meanwhile D-Ala may be related to circadian rhythm as hypothesized by 
Morikawa and co-workers
27, 28
. The detected amount of D-Ala release per islet was 0.14 fmol per 
islet and corresponds to 0.08 % of the D-Ala amount in a whole islet. Even though further 
experiments with larger numbers of islets is required to collect releasate with higher D-Ala 
concentration for confident quantitative analysis, it is possible to say that enough amount of D-
Ala is stored in islets to respond to change in extracellular D-glucose concentration. This islet 
response is correlated to change in physiological state, perhaps induced as a response to feeding 
behavior by detecting increased level of blood glucose. 
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5.6 Figures 
 
Figure 5.1. Chiral separation of standard amino acids with fluorescein by non-aqueous CE. 
Each amino acid is 1 µM and fluorescein concentration is 2 µM. Separation buffer contained 40 
mM HP-γ-CD, 80 mM CS, 80 mM QN, and 10 mM sodium acetate in FA. The separation was 
performed with 27 kV normal polarity over 80 cm of bare fused-silica capillary. Capillary had 75 
µm i.d. and detection window at 70 cm from the inlet.  
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Figure. 5.2. Enzymatic oxidation of D-Ala. (a) 1 µM each of Ala enantiomers at 0 h incubation 
with DAAO (top) and the same sample after 1 h incubation at 37°C (bottom). The separation 
condition was the same as described in Figure 5.1. DAAO Incubation condition: 1 h incubation 
at 37C for 0.5 µL of 100 µM L- and D-Ala in PBS that were mixed with 0.25 uL each of DAAO 
(15 U/mL), catalase (15.6-62.5 U/mL), and FAD (5 mM) in PBS.. (b) D-Ala is oxidized by 
DAAO at the presence of the cofactor FAD that is regenerated by the activity of catalase.  
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Figure. 5.3. A typical separation of islets homogenate sample. An islet sample with no 
enzymatic treatment (bottom) and the same sample with enzymatic treatment (top) are shown. D-
Ala peak in the original sample disappeared by 1 h of DAAO digestion at 37°C. The separation 
condition was the same as described in Figure 5.1. 
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Figure. 5.4. D-Ala analysis in releasate of islets cells before and after 25 mM D-glucose 
stimulation. (a) 40-fold concentrated releasate after D-glucose stimulation, (b) the same sample 
as (a) with 100 nM D-Ala spike, (c) 50-fold concentrated releasate control (before D-glucose 
stimulation), and (d) the same sample as (c) with 100 nM D-Ala spike. D-Asp peak appeared only 
after D-glucose stimulation. The releasate samples (a) and (c) were obtained from the same 
isolated islets. Twenty islets were used for this experiment. 
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Chapter 6 
 
Development of D-Amino Acid Peak Identification 
Methods Coupled with Chiral Separation via Capillary 
Electrophoresis 
 
 
This chapter introduces several D-amino acid (D-AA) separations for free D-AAs as well as D-
AAs from peptides that contain D-AA residues. In Chapter 1, several analytical techniques for D-
AA research were briefly introduced (section 1.5). In this chapter, I describe how to confirm D-
AA peaks in a complex separation: D-AA identification via biochemical sample pre-treatments 
and CE-based techniques for both free and peptide-residue D-AAs. Developing these methods is 
critical to obtain reliable qualitative and quantitative D-AA information. I acknowledge Liping 
Wang for the enzyme purification approaches. The enzyme expression and purification 
procedures are adapted from Liping Wang's published study
1
. I also appreciate the help given by 
Nick Creek, a chemistry undergraduate student, who worked with me on a non-aqueous CE 
project to contribute to establish some separation modes. Also, I would like to thank Lu Bai for 
her work on D-amino acid containing-peptide project in which she gave me insightful 
suggestions and prepared samples through liquid chromatography separation for primary 
screening and peptide hydrolysis for peptide residue analysis.  
 For the work on electrospray ionization-mass spectrometry (ESI-MS) detection coupled 
with chiral separation by capillary electrophoresis (CE). I greatly appreciate for support given by 
Jordan Aerts and Jingxin Liu to teach me ESI-MS operation and to help ESI-MS optimization. I 
am also grateful to Yi Zhang who worked with me to establish chiral CE-ESI-MS method. Her 
wonderful work resulted in effective chiral CE-laser-induced fluorescence (LIF) separation that 
could be transferred to CE-ESI-MS. 
6.1 Introduction 
6.1.1 Identification of free D-amino acids 
 Identification of free D-amino acids (D-AAs) that are found in animals has analytical 
importance and requires careful experiment design. A major analytical challenge is that 
distinguishing D-AA signals from abundant L-AA signals. Thus, a variety of detection methods 
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are coupled with separations. Some common separation methods for endogenous D-AA analysis 
include capillary electrophoresis (CE) and liquid chromatography (LC)
2, 3
 due to their 
compatibility with multiple detection options. Mass spectrometry (MS) is an attractive detection 
method that can identify diverse molecular species. Meanwhile, MS itself cannot distinguish 
enantiomeric molecules because they have the same mass. Even with tandem MS, it is still 
difficult to distinguish enantiomers due to similar chemical and physical properties.  
 Several reports describe MS detection coupled with chiral separation by CE on-line
4, 5
 
and off-line
6
. These coupling methods still remain challenging and there are some useful 
coupling methods reported. One method, the partial filling method
5, 7
, uses a buffering zone 
before an electrospray ionization (ESI) source. With the partial filling method, the buffering zone 
contains minimum chemical additives that contaminate the ionization source and may 
accumulate in the ESI-MS interface. Other methods include modification with chiral selectors
8, 9
 
and capillary wall coating
4, 10, 11
. These methods reduce the amount of chemical additives in the 
chiral separation solution; modified chiral selectors can possess better chiral separation 
capability or have a suitable electronic charge which helps migration of the chiral selectors 
toward the inlet of capillary. All of these analytical modifications protect sensitive MS 
instrumentation and reduce background signal due to chemical additives in CE separation 
solution.   
 Besides modification of analytical methods, sample treatment by biochemical techniques 
is an effective and well-established method and can verify the presence of a specific molecules 
such as D-AA,. In the biological world, chirality is critical because it influences ligand-substrate 
binding. For D-AAs, there are known enzymes, such as D-amino acid oxidase (DAAO) and D-
aspartate oxidase (DAspO)
12, 13
 that accept D-AA as their ligand. Antibodies are an alternative 
option which is useful to identify specific molecular target. In general, antibodies can recognize 
molecular target that is above a specific size. Thus, it is rare to find an antibody that can 
recognize a target D-AA, not D-AA conjugated to a large molecule like protein, by distinguishing 
it clearly from other similar molecules. In this chapter, both analytical and biochemical methods 
for D-AA peak identification and validation are discussed, then the established peak 
identification method is applied to D-glutamate (D-Glu), an intriguing free D-AA found in the 
animal central nervous system (CNS)
14-16
, as an application to biological samples. 
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6.1.2 Identification of D-amino acid residue in peptides 
 D-AA can be found as a residue in peptides or proteins. These D-AA containing-peptides 
(DAACPs) can be produced by post-translational modification
17
 or nonenzymatic isomerization 
of L-amino acid residue into D-isomer form
18
. There are a few reports discussing robust DAACP 
detection and identification methods like enzymatic digestion
19
 and MS-based method
20, 21
 while 
adding separation step to DAACP analysis can simplify the overall procedure or can make 
identification of putative DAACPs more confidently. 
 The available methods for DAACP residue analysis are similar to the methods used for 
free D-AAs. Thus, the analytical and biochemical methods discussed above can be utilized for 
DAACP identification as well. In addition, single-residue isomerization can result in totally 
different molecular shapes between whole peptides of DAACP and the corresponding all-L-
amino acid peptide
22, 23
. Therefore, the separation of these diastereomers can be easier than 
enantiomeric pair of amino acids because chiral selectors can distinguish more emphasized shape 
difference of peptide diastereomers. This can result in that smaller amount of chiral selectors is 
required for chiral separation so that the separation can achieve faster separation speed, less 
expense for preparing solution, and/or more compatible detector options available. 
6.2 Experimental Setup 
6.2.1 Reagents 
 Ultra pure de-ionized water was prepared by Milli-Q filtration system (Millipore, Belford, 
MA). Authentic amino acids were purchased from Sigma-Aldrich (St. Louis, MO) and stored as 
solutions by dissolved in 100 mM borate (pH 9.5) buffer. Naphthalene-2,3-dicarboxaldehyde 
(NDA), potassium cyanide (KCN), and Dynabeads® M-270 Epoxy kit were purchased from 
Invitrogen (Grand Island, NY). Anti-D-Glu-glutaraldehyde (G)-protein antibody (hereafter, anti-
D-Glu antibody) is purchased from US Biological (Marblehead, MA). For capillary coating, 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane (PEGylation reagent) was purchased from 
Gelest (Morrisville, PA), poly(ethylene oxide) (PEO) was purchased from Sigma-Aldrich, and 
UltraTrol
TM
 LN (UTLN) was purchased from Target Discovery (Palo Alto, CA). For non-
aqueous CE work, a variety of cyclodextrins were purchased from Sigma-Aldrich except 
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quaternary ammonium β-CD (QA-β-CD) and hydroxypropyl quaternary ammonium γ-CD (QA-
γ-CD) that were purchased from CTD Holdings Inc. (Alachua, FL). 
6.2.2 CE-LIF instrumentation and sample analysis 
Separations were performed using an automated P/ACE MDQ CE system equipped with 
LIF detection (Beckman Coulter). The CE system was coupled to an external diode laser 
56ICS426 (Melles Griot) emitting 440 ± 8 nm, with the coupling performed via a fiber optic 
cable (OZ Optics). The laser power was adjusted to 3 milliwatt at the output terminus of the optic 
cable to avoid damage to the photomultiplier tube (PMT). A band-pass filter of 490 ± 15 nm 
(Omega Optical), located prior to the PMT, selects the appropriate fluorescence emission band 
for detection. For separations and capillary coating, uncoated fused-silica capillaries of 75 µm 
inner diameter (ID) and 360 µm outer diameter (OD) (Polymicro Technologies) were used. 
Capillaries were injected with 0.1 M NaOH at a pressure of 30 psi for 1 min and allowed to be 
primed in NaOH for 25 min before their initial use. Samples were introduced into the capillaries 
by pressure injection of 0.5 psi for 5 s.  
The length of separation capillary varied as there was a range of goals. When aqueous 
separation buffer was used, total length of the capillary was 80 cm with an effective length of 70 
cm to the detection window. For non-aqueous separation, total length of 40 cm (30 cm effective 
length) was used for uncoated capillary and total length of 60 cm (50 cm effective length) for 
coated capillary. Separations were carried out by applying 27 kV of normal polarity for 
separations with uncoated capillary or 27 kV of reverse polarity for separations with coated 
capillary. Between two runs, the capillaries were rinsed with methanol (30 psi, 1 min), 0.1 M 
NaOH (30 psi, 1 min), and separation buffer (30 psi, 1 min). For analysis of peak areas in 
electropherograms, the obtained CE-LIF results were analyzed using Origin 8 software (Origin 
Lab Corp.). 
6.2.3 Derivatization for amino acid-samples 
 For NDA derivatization, authentic amino acid sample (1 µL) was mixed with 2 µL NDA 
(10 mM in methanol) and 2 µL KCN (20 mM in 100 mM borate, pH 9.5) solutions. The mixture 
was allowed to react for 30 min in dark at room temperature. Once reaction was complete, the 
mixture was diluted with water to obtain appropriate concentration of N-substituted 1-
cyanobenzo isoindole (CBI)-amino acids for CE measurement. 
  112 
6.2.4 Antibody-magnetic bead conjugation for peak identification 
 Anti-D-Glu antibodies were coupled with Dynabeads® (hereafter magnetic beads or MB) 
by following the instruction given by the manufacture. In short, 1 mg of MB was washed to 
activate epoxy group that was used to couple antibodies on MB. The activated MB was 
incubated with anti-D-Glu antibody for overnight at 37 °C, then the remaining epoxy group on 
MB was eliminated by overnight incubation with glycine. After the incubation, the antibody-MB 
conjugate was washed multiple times and then re-suspended in storage buffer to be stored at 4 °C 
until use. The final concentration of the antibody-MB conjugate was 10 mg of antibody-coupled 
MB per mL of solution. 
 For D-Glu peak identification, 1 µL of analyte solution was mixed with 3 µL of antibody-
MB for 1 h at room temperature. Then, antibody-MB was discarded once collected by magnet 
while supernatant was derivatized with NDA and KCN for CE-LIF measurement as described 
above. To check the effectiveness of the antibody-MB conjugate, control experiment was 
performed with standard amino acid solution incubated with the anti-D-Glu antibody only. 
6.2.5 Enzyme digestion of D-amino acids 
6.2.5.1 D-Aspartate oxidase (DAspO) expression and purification 
 Protein expression and purification reagents were purchased from EMD Chemicals unless 
otherwise specified. E. coli containing mouse daspo gene with His tag and ampicillin resistance 
was prepared by Liping Wang and DAspO-expressing E.coli was grown in 250 ml of Luria-
Bertani broth supplemented with 100 µg/mL ampicillin at 37 °C until the optical density at 600 
nm reached 0.4–0.5. The daspo gene expression was then induced by adding 2.5 µL of 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and the culture continued at 17 °C for 20 h. 
Soluble His tag protein was obtained by lysing the cells with BugBuster Mix (lysing solution) 
and nickel-nitrilotriacetic acid (NiNTA) purification. All purification procedures were performed 
at 4 °C. Briefly, bacterial cells were lysed in the presence of protease inhibitor mixture and 
dithiothreitol (DTT). Cleared lysate was incubated with bulk NiNTA resin for 1 h. The resin was 
then packed into a 24-ml Econo column (Bio-Rad Laboratories) by gravity. The column was 
washed and protein eluted with a NiNTA wash and elution buffer. The eluted protein was 
concentrated down to 2 mL and subjected to gel filtration chromatography with a HiPrep 
Sepharcryl 200 HR 16/60 column (GE Healthcare Life Sciences) using 50mM Tris-HCl buffer, 
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pH 8.0, and 2mM DTT following product instructions. Protein fractions with enzyme activity 
were concentrated and stored in a solution of 50 mM NaPO4, 150 mM NaCl, pH 8.0, 25% 
glycerol, and 1 mM DTT. Protein concentration was determined with a BCA kit (ThermoFisher 
Scientific) with a spectrophotometer, Spectramax (Molecular Devices, Sunnyvale, CA) . 
6.2.5.2 D-Glu and D-Asp oxidation by DAspO 
 One µL of the solution containing 500 µM each of Glu and Asp enantiomer pairs in 100 
mM pyrophosphate (pH 8.0) was mixed with 1 µL of 2 mM flavin adenine dinucleotide (FAD) 
as cofactor and 1 µL of DAspO solution in phosphate buffered saline. The mixture was 
incubated in water bath at 37 °C for various period of time to record the time course of D-Glu/ D-
Asp digestion by DAspO. When incubation is finished, 0.5 µL of the incubated mixture were 
allowed to react with 1 µL of 10 mM NDA and 1 µL of 20 mM KCN for 30 min in dark at room 
temperature to form CBI-amino acids. Once derivatization was completed, the NDA-derivatized 
sample was diluted with appropriate amount of water.  
6.2.6 Non-aqueous capillary electrophoresis (NACE) 
6.2.6.1 Various combinations of non-aqueous solvent and chemical additives 
 Non-aqueous separation solutions were made with a variety of combinations of non-
aqueous solvent, CD, and other chemical additives. Non-aqueous solvents are methanol, ethanol, 
acetonitrile, acetic acid, formamide (FA), and N-methyl formamide (NMF). Chemical additives 
were CD, electrolyte, surfactant, and/or chiral selector(s). The CDs used in separation buffer 
were α-CD, β-CD, γ-CD, sulfated β-CD, hydroxypropyl β-CD (HP-β-CD), carboxymethyl β-CD, 
methyl β-CD, hydroxypropyl γ-CD (HP-γ-CD), quaternary ammonium β-CD (QA-β-CD), 
hydroxypropyl quaternary ammonium γ-CD (QA-γ-CD). The other chemical additives, including 
sodium dodecyl sulfate (SDS), SDC, sodium cholate, citrate, sodium tetraborate decahydrate, 
(1S)-(+)-camphorsulfonic acid (CS), quinine (QN), and (8S,9R)-(−)-N-benzylcinchonidinium 
chloride (BC), are purchased from Sigma-Aldrich. 
6.2.6.2 Capillary coating 
 Three types of capillary coatings were performed to give neutral charge on the inner 
surface of bare-fused silica capillary. PEO coating was applied to bare-fused capillary by 
following a method previously described
24, 25
. PEO stock solution was made by 10 mg PEO 
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dissolved in 4.5 mL water with vigorous stirring of PEO solution by a magnetic bar for overnight. 
Then, fresh PEO solution was prepared by mixing 180 µL of PEO stock solution and 20 µL of 
HCl (1 M in water). At the beginning of a day, capillary was initiated by wash with water (2 min, 
30 psi), 0.1 M HCl (5 min 30 psi), PEO solution (5 min, 30 psi), and then water (2 min, 30 psi). 
Before each run, PEO coating was refreshed by wash with water (3 min,30 psi), PEO solution (5 
min, 30 psi), and then separation buffer (2 min, 30 psi). 
 PEGylation coating method has been reported previously for surface modification of 
microchip device
26
. PEGylation coating was applied to new capillary by wash with 1 M HCl (30 
psi, 1 min) and waiting for 40 min to protonate silanol group of capillary inner surface, brief 
water rinse (30 psi, 1 min), drying out the inside of capillary by 2 h of N2 gas flow, wash with 
PEGylation reagent (50 psi, 20 min) and waiting for 30 min, and finally water rinse for 4 h with 
the rate of 0.5 mL/h. Once PEGylation coating was applied to a capillary, the coating last for one 
month. 
 UTLN coating was applied by following the manual given by the manufacture. For a new 
capillary, preconditioning was carried out by wash with methanol (5 min, 30 psi), water (1 min, 
30 psi), 1 M HCl(aq) (5 min, 30 psi), water (1 min, 30 psi), and then 1 M NaOH (10 min, 20 psi). 
Dynamic coating of UTLN is done before each run by wash with 1 M NaOH (1 min, 30 psi), 
water (1 min, 30psi), UTLN (2 min, 20 psi), and then separation buffer (2 min, 20 psi).  
6.2.7 Aplysia californica CNS sample preparation and analysis 
A. californica (approximately 200-300 g) were obtained from University of Miami 
Aplysia Research Facililty (Miami, FL) and anethetized by injecting isotonic MgCl2. into the 
body cavity before dissection. The anesthetized animals were then dissected to obtain cerebral 
and plural ganglia. Under microscope, the obtained ganglia in artificial sea water (460 mM NaCl, 
10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, and 10 mM HEPES at pH 7.8) were manipulated to 
obtain ganglion clusters. The isolated ganglion clusters were placed in 44 mM pyrophosphate 
buffer (pH 8.0). Before use, the ganglion cluster samples were sonicated and centrifuged. The 
supernatant of the sample (0.5 µL) was then derivatized with 1µl of 20 mM NDA and 1µl of 20 
mM KCN for 30 min. The derivatized samples were diluted with appropriate amount of water.  
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6.2.8 Instrumentation of CE coupled with electrospray ionization-mass spectrometry 
(ESI-MS) 
 In CE-ESI-MS experiments, all chemicals except cyclodextrin were LC-MS grade and 
purchased from Fluka (St. Louis, MO). The injection and inlet parts of the CE were set in an 
acrylic box equipped with safety interlocks. The injection stage was connected to a Bertan high-
voltage power supply (Valhalla, NY) to apply voltage across capillary for CE separation. For 
ESI-MS detection, micrOTOF ESI-TOF-MS system (Bruker Daltonics, Billerica, MA) was 
equipped with a commercial CE-ESI-MS sprayer kit (G1607A) (Agilent Technologies, Santa 
Clara, CA). The ion optics were tuned for the mass range of 100-500 m/z. Calibration was 
performed by sodium formate clusters from a direct infusion of 100 μg/mL sodium formate in 
water at 1 μL/min.  
 For separation using a capillary with PEGylation coating, the separation buffer consisted 
of 20 mM γ-CD in 40 mM ammonium formate aqueous solution, background electrolyte (BGE) 
solution of in 40 mM ammonium formate aqueous solution, and sheath liquid consisted of 5 mM 
ammonium formate aqueous solution with 50% (v/v) methanol were used. For separation using 
uncoated capillary, separation buffer consisted of 0.65 mM QA-β-CD and 4.35 mM QA-γ-CD in 
5 mM ammonium formate aqueous solution with 50% (v/v) methanol, BGE solution of in 5 mM 
ammonium formate aqueous buffer with 50% (v/v) methanol, and sheath liquid consisted of 5 
mM ammonium bicarbonate and 5 mM ammonium hydroxide in 1:1 volume ratio of water and 
methanol were used. Between each separation, capillary is briefly rinsed by water (2 min) 
followed by the separation buffer (1 min) and then the capillary inlet was placed into a stainless 
steel buffer vial filled with BGE solution. For sample injection, standard CBI-AA solutions were 
placed into a custom-fabricated stainless steel nanovial. Sample was hydrodynamically injected 
by maintaining a height difference of 15 cm between the capillary inlet and outlet for 1 min. CE 
separation was performed by applying  -15 to -27 kV to the inlet and hydrodynamic pressure was 
applied by elevating inlet side of capillary by maintaining a height difference of 10 cm for 
separations with uncoated capillary. The parameters of ESI were set for each type of separation. 
For separations with PEGylation capillary, dry gas of 6 L/min at 200°C, 1.5 bar nebulizer gas, 
and 3.5 µL/min of sheath liquid flow rate. Positive ionization mode was selected with capillary 
voltage of 4.5 kV and end plate offset at -0.5 kV for this separation. For separations with 
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uncoated capillary, dry gas of 3 L/min at 180°C, 0.3 bar nebulizer gas, and 2.5 µL/min of sheath 
liquid flow rate. Negative ionization mode was selected with capillary voltage of -4.0 kV and 
end plate offset at 0.5 kV for this separation. 
6.2.9 Peptide residue and whole peptide analysis for D-amino acid containing-peptides 
(DAACPs) measurement 
 Synthetic peptides, NWF-amide (NWFa), GFFD, FMRF-amide (FMRFa), and the 
corresponding three analogues with D-amino acids in the second position were synthesized by 
the Protein Sciences Facility, University of Illinois at Urbana-Champaign. Candidate peptides in 
biological samples were prepared by Lu Bai through aminopeptidase M digestion followed by 
HPLC separation. 
 Peptide standards and samples obtained from HPLC eluent fractions were hydrolyzed by 
one of the following method: (1) Liquid-phase hydrolyzation (LPH), (2) Long vapor-phase 
hydrolyzation (VPH), and (3) Short VPH. In LPH, peptide standard and samples were dried by 
vacuum concentrator and mixed with 0.3 mL of 6 M HCl. Then, the peptide-HCl mixture was 
hydrolyzed in a glass tube in which peptide solution was continuously heated for overnight. The 
hydrolyzed peptide mixture was stored in -80°C until it was used for CE-LIF measurement. The 
hydrolyzed peptide mixtrue was neutralized with an equivalent moles of NaOH (10 M), then 2 
µL of neutralized mixture was derivatized by 2 µL NDA (10 mM in methanol) and 2 µL KCN 
(20 mM in 100 mM borate, pH 9.5) solutions for 30 min at room temperature in dark. In VPH, 
peptide standard and samples were hydrolyzed in microwave with HCl vapor at 150°C for 30 
min (long VPH) or 2 min (short VPH). The hydrolyzed peptides were neutralized with NaOH, 
then derivatized by NDA and KCN as described for LPH. The derivatized peptide residues were 
diluted with water to obtain appropriate concentration and were subjected to CE-LIF analysis. 
 Whole peptide analysis was carried out by labeling peptides with Pacific Blue® 
succinimydal ester (PBSE). Peptide standards were dissolved in 100 mM carbonate buffer (pH 
8.3) while peptide samples collected from LC fractions were dried by vacuum evaporator and 
then re-suspended in the carbonate buffer. Peptide solution (1 µL) was mixed with equal volume 
of PBSE (20 mM in the carbonate buffer) solution and was allowed for derivatization for 1 h at 
room temperature in dark. After derivatization, the mixture was diluted with water to obtain 
appropriate peptide concentration and was used for CE-LIF analysis. 
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6.3 Results and discussion 
6.3.1 Antibody-magnetic bead conjugation for D-Glu peak identification 
 CE-LIF analysis showed diminished intensity of CBI-D-Glu peak of standard amino acid 
sample, containing enantiomer pairs of Glu and Asp, after incubation with MB solution that was 
incubated with anti-D-Glu antibody (Figure 6.1). This indicated that the antibody was 
successfully conjugated with MB. However, D-Glu peak was not completely eliminated by the 
antibody-MB conjugate (Figure 6.1b) even with increased amount of the antibody-MB conjugate 
or extended period of incubation with amino acid standard (Figure 6.1c). Comparing with the 
results of control experiment that used only antibody to incubate with standard amino acid, the 
antibody-MB conjugate showed slightly better D-Glu peak elimination (Figure 6.1e). In addition, 
the antibody-MB conjugate lost its activity after overnight storage at 4°C (Figure 6.1d). These 
results may indicate that MB is capable for keeping relatively large amount of antibody 
functional by avoiding antibody-antibody tangle when the antibody-MB solution is in slurry 
form, but it loses its capability once the antibody-MB is precipitated. Once precipitation occurs, 
fully restoring the ability of the antibody is difficult even sonication is applied to the solution of 
the precipitated antibody-MB conjugate (data not shown). 
 Furthermore, the antibody-MB conjugate also diminished CBI-D-Asp peak besides CBI-
D-Glu peak was diminished. This unspecific binding occurred probably because the antibody is 
designed to bind specifically to D-Glu-G-protein conjugate rather than to free D-Glu
27
. When the 
antibody-MB conjugate with NDA-derivatized standard amino acids, neither peak of CBI-D-Glu 
nor CBI-D-Asp was diminished (data not shown). Considering the fact that glutaraldehyde reacts 
with the amino group, the antibody is likely to recognize the portion of D-Glu-G-protein from the 
D-Glu terminus to the conjunction of G and N-terminus of the protein (Fig 6.1f).  
6.3.2 Enzyme digestion of D-amino acids 
 When standard amino acid sample, containing D-Asp and D-Glu, is incubated with 
DAspO and FAD, CE-LIF showed that the peaks of CBI-D-Asp and CBI-D-Glu were diminished 
as incubation time increased (Fig 6.2a). The initial setting of DAspO digestion showed complete 
CBI-D-Asp peak elimination within 2 h of incubation while CBI-D-Glu peak reached to plateau 
after 24 h of incubation. The DAspO used for this experiment was derived from mice and it 
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agreed well with previously published results that D-Asp was digested faster than D-Glu was
28
. 
To achieve complete CBI-D-Glu peak elimination, higher concentrations of DAspO and FAD 
were required. Under this condition, D-Glu was quickly digested without reaching to plateau (Fig 
6.2b). 
6.3.3 Non-aqueous capillary electrophoresis (NACE) 
 Large changes in separation conditions provide diverse separation results and can greatly 
increase the chance of target peak isolation and the reliability of peak identification. First of all, 
solubility of various CDs in different solvents was checked. Next, the solutions in which one 
type of CD is successfully dissolved in one type of solvent were used for NACE-LIF to check 
separation capability for CBI-amino acids (Gly, Ser enantiomers, Asp enantiomers, and Glu 
enantiomers). If a separation solution showed (1) at least 4 isolated peaks or (2) less than 4 
isolated peaks but one or more peak(s) were composed of partially merged multiple peaks, the 
separation solution was retained for further modification to increase chiral separation capability. 
Then another chemical additive (electrolyte, surfactant, or chiral compound) was added to the 
retained separation solutions to check the difference of separation capability. In general, addition 
of electrolyte did not improve chiral or achiral separation capability while some chiral 
compounds significantly improved chiral separation results (Fig 6.3a). Among them, CS and 
quinine QN usually provided better separation capability to CD-containing separation solutions. 
In terms of solvent type, FA and NMF could dissolve most of CDs and chemical additives and 
provided some useful separation modes due to giving different environment from aqueous 
solution, like ionic strength, binding profiles between CDs and analytes, and inner surface 
condition of capillary as discussed in literature
29, 30
. Acetic acid was difficult to use as the main 
solvent for CE due to its high conductivity but it could be used to lower pH* of non-aqueous 
solvent. Methanol, ethanol, and acetonitrile were not compatible with most of CDs, thus they 
were used as mixture with FA- or NMF-based solutions. These mixed organic solvents could 
slow down migration speed of analytes so that they could be used to enhance resolutions of 
enantiomer peaks unless peak broadening occurred. 
 Capillary coatings with PEO and PEGylation reagent were established to work with 
reverse polarity CE (Fig 6.3b) while separation with UTLN coating showed broader peaks than 
the same separation condition with PEO or PEGylation coating. Since PEGylation coating lasts 
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for a month, it was used for most of reverse polarity NACE-LIF due to convenience. In reverse 
polarity NACE-LIF, the peak of sample solvent plug, a small negative peak found in normal 
polarity NACE-LIF and appearing before CBI-amino acid peaks, was not observed before all 
CBI-amino acid peaks were observed in both PEGylation and PEO coating capillaries. This 
indicated that these neutral capillary coatings suppressed electroosmotic flow effectively. 
 In terms of the effect of CDs on chiral separation capability, β-CD and its derivative CDs 
generally possessed effective chiral separation capability for CBI-Asp enantiomers. In contrast, 
only partial separation of CBI-amino acids was observed when separation solutions contained α-
CD, γ-CD, γ-CD derivative CDs. However, some of these separation solutions showed excellent 
separation results when chiral selectors were added. Especially, the combination of CS and QN 
added to α-CD, γ-CD, or HP-γ-CD resulted in baseline separation of enantiomeric pairs of CBI-
Glu, CBI-Ser, and/or CBI-Asp (Fig 6.3c). Acidic CDs (carboxymethyl β-CD and sulfated β-CD) 
did not show effective chiral separations maybe because they could have negative charge in 
neutral/basic pH buffer due to their low pKa and their negative charge prevented interaction with  
negatively charged CBI-amino acids. With neutral capillary coating, addition of BC to the 
separation solution containing QA-β-CD or QA-γ-CD enhanced resolution of CBI-Asp or CBI-
Glu enantiomeric peaks, respectively.  
6.3.4 Analysis of D-Glu in A. californica CNS by NACE-LIF with DAspO treatment 
 Based on the developed NACE separation and D-AA peak identification by DAspO, D-
Glu in A. californica CNS was measured. For quantitative analysis of D-Glu, it was desired to 
have baseline separation of Glu enantiomers. The NACE separation solution of 50 mM α-CD, 25 
mM CS,  and 50 mM QN (pH* 9.1) in FA fulfilled this requirement. Figure 6.4a shows a typical 
separation of a CNS ganglia sample obtained from A. californica. The putative D-Glu peak in 
ganglia sample was identified by sample pretreatment with DAspO. Through DAspO treatment, 
D-Glu and D-Asp peaks were removed (Fig 6.4b) and peak areas of D-Glu and D-Asp were 
quantified to compare with peak areas of the corresponding L-isomers. The percentage of D-
isomer from total Glu was approximately 0.1% in all measured Aplysia ganglia while the amount 
of D-Asp was found to be more than 35% of total Asp in the same ganglia samples (Fig 6.4c). 
The obtained D-Glu value agrees previously reported D-Glu amount in rat brain
14, 15
. Therefore, 
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the NACE separation and peak identification method by DAspO have shown useful for the 
analysis of endogenous D-AA found in small amount. 
6.3.5 Electrospray ionization-mass spectrometry (ESI-MS) 
 For optimization of CE separation that was aimed to couple with ESI-MS, aqueous and 
non-aqueous separation buffers were used to check chiral separation capability for CBI-Asp and 
Ser with CE-LIF described above with applying reverse polarity across capillary. Among diverse 
solvents tested for chiral CE separations, aqueous separation buffer was found to be useful in 
terms of resolution of enantiomeric pairs of analytes, relatively fast separation speed, and 
relatively volatile than some solvent such as FA and NMF. Then the selected CE-LIF separation 
conditions were used for CE-ESI-MS: one separation condition used capillary with PEGylation 
coating and separation buffer using neutral cyclodextrin (γ-CD) and the other condition used 
uncoated capillary with positively charged cyclodextrin (QA-β-CD and QA-γ-CD). In CE-LIF, 
only the inlet of capillary was placed in separation buffer containing cyclodextrin and the outlet 
was placed in solution which was same as separation buffer without containing cyclodextrin. 
This setting was used to mimic CE-ESI-MS setting as much as possible. Through modifying 
separation conditions, it is noteworthy that chiral separation capability was not significantly 
affected by solution at capillary outlet which contained ammonium salt (either ammonium 
hydroxide, ammonium formate, or ammonium bicarbonate) with or without formic acid maybe 
because the anion of ammonium salt did not enter the capillary due to electric attraction by the 
anodic electrode. The solution at capillary outlet of CE-LIF and sheath liquid in CE-ESI-MS had 
similar role for CE separation, thus indifferent separation results by using different solutions at 
capillary outlet in CE-LIF could mean that sheath liquid in CE-ESI-MS affects efficiency of 
analyte ionization but not chiral separation. Meanwhile outlet-side solution without ammonium 
salt such as 0.1% formic acid in water disturbed chiral separation of CE. Therefore, it was 
decided to make a sheath liquid containing ammonium salt for ESI-MS. Another important point 
was both types of separations effectively reduced electroosmotic flow due to capillary surface 
modification. As discussed above, PEGylation coating provides a neutral charge on inner surface 
of the capillary. This coating was permanent due to covalant bonds formed between PEGylation 
reagent and silanol group, thus capillary re-conditioning was not necessary. On the other hand, 
the separation with cationic cyclodextrin and uncoated capillary reduced electroosmotic flow in a 
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different reason; cationic cyclodextrin was electrostatically adsorbed to negatively charged 
silanol group. Thus, reproducible separation may be due to replenishing cationic cyclodextrin on 
capillary surface when capillary was rinsed by separation solution. These separation conditions 
verified by CE-LIF were transferred to CE-ESI-MS. In CE-ESI-MS, it was necessary to modify 
nebulizer gas setting or hydrodynamic pressure by maintaining height difference between 
capillary inlet and outlet, otherwise analyte peaks did not appear probably because sample plug 
was driven toward inlet due to initial backward pressure caused by nebulizer gas. This 
phenomenon could be avoided by turning off nebulizer gas for first few minutes in PEGylation 
coating method, or by applying hydrodynamic pressure toward ESI source in cationic adsorption 
method. The separation results in CE-ESI-MS are shown in Figure 6.5. Applying these 
modifications, however, resulted in unstable spraying due to no nebulizer gas at the beginning of 
separation or disturbed chiral separation due to insufficient time for analyte-cyclodextrin 
interaction.  
 Comparing these CE-ESI-MS results with the corresponding separations in CE-LIF, one 
major challenge was significantly decreased chiral resolution of enantiomeric pairs. A major 
reason of reduced chiral separation capability was nebulizer gas pressure and hydrodynamic 
pressure. In PEGylation coating method, nebulizer gas was set to 1.5 bar after the first few 
minutes of no nebulizer gas. This nebulizer gas setting helped to reduce period of unstable 
spraying so that ESI became stable when analytes came out. Meanwhile this setting could also 
cause reduced time of analyte-cyclodextrin interaction. Therefore, both high nebulizer gas 
pressure and hydrodynamic pressure applied to capillary lead reduced chiral separation 
capability. To improve chiral separation capability, these setting need to be modified since too 
high concentration of cyclodextrin induce suppression of ionization
31, 32
. Another difficulty 
associated with CE-ESI-MS separations was corrosion of ESI sprayer tip. Gradual corrosion 
seemed to happen by slow deposit of cyclodextrin at the sprayer tip that may have increased the 
chance of corona discharge. In terms of electrophoretic mobility, γ-CD had neutral charge to 
possess no electrophoretic mobility and positively charged QA-β-CD and QA-γ-CD had 
electrophoretic mobility toward the inlet. However, it was possible that both types of CD had 
apparent mobility due to high nebulizer gas and hydrodynamic pressure, respectively. Therefore, 
further modification of nebulizer gas, hydrodynamic pressure, and cyclodextrin concentration in 
separation buffer was desired to improve overall CE-ESI-MS performance. 
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6.3.6 Analyses on whole peptide and amino acid residues of D-amino acid containing-
peptides (DAACPs) 
 Both whole peptide and amino acid residue separations were established with standard 
samples. The peak intensities of amino acid residues were quantified with standard FMRFa to 
check if hydrolysis was complete. Both short and long VPH methods gave roughly the same 
intensity per amino acid residue while LPH showed clearly different intensities of each amino 
acid residue (Figure 6.6). Thus, it was clear that VPH methods more quickly and effectively 
hydrolyzed the standard peptides than LPH method for an overnight period. Meanwhile, the 
separations of hydrolyzed peptide samples showed isomerizations of a few amino acid species. 
The degree of isomerization depended on peptide hydrolysis methods: LPH method gave least 
isomerization and long VPH showed most isomerization (Figure 6.6). These results indicated 
that short VPH method worked well for peptide residue analysis because it showed complete 
hydrolyzation of peptides without isomerizing amino acid residues too much. Thus, this method 
was used for further residue analysis on the hydrolyzed LC-fraction biological samples. Some 
representative separation results of the LC-fraction samples are shown on Figure 6.7 and each 
sample showed more peaks than the number of peaks expected from the amino acid residues of 
the peptide mass-matched from MS analysis. Some unexpected peaks could be other compounds 
collected in the same LC-fraction while others could be NDA byproduct peaks. Even though 
spiking experiments with D-AA standards indicate which peaks were potentially the target 
residue peaks, it was difficult to quantify the amount of the target peptide from the peak 
intensities due to the possible interference. 
 Whole peptide analysis with PBSE labeling worked well for authentic peptide standards 
(Figure 6.8a). The separation was successfully carried out with two separation solutions: the 
solution containing 40 mM β-CD and 60 mM SDC in 200 mM borate (pH 9.5) and the solution 
containing 150 mM HP-β-CD and 50 mM SDS in 100 mM Tris-borate buffer (pH 9.0). In the 
separation results, Pacific Blue (PB)-labeled peptide peaks appeared without interference of the 
PBSE and the hydrolyzed PBSE (PBSE losing succinimydal ester group) peaks (Figure 6.8b). 
This was an advantage to confidently find the target peptide peaks for peptide quantitation. The 
LC-fraction samples, however, showed no sign of the target peaks (Figure 6.8c). This result may 
have been caused by low concentration of the target peptide that was below LOD of the method, 
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otherwise labeling method was disturbed due to the unexpected solution condition, such as 
unsuitable pH for derivatization, by mixing LC-fraction and derivatization bicarbonate buffer. 
6.4 Conclusions 
 A variety of separation and sampling handling approaches have been developed for D-AA 
separations.  In addition, approaches to validate the peak identity have been tested. For peak D-
AA identification, sample treatment by the appropriate degradation enzyme for specific D-AAs is 
a useful and compatible with NDA derivatization and CE-LIF measurement like the D-Glu peak 
identification described above. 
 DAspO can digest D-Asp and D-Glu, the D-AAs found in animal nervous systems
28, 33-35
. 
DAAO is also useful for digesting many D-AAs except D-Asp and D-Glu
12, 36
. Thus, DAAO is 
helpful for peak identification for D-AAs in biological samples
37
. In contrast, the method using 
antibody is not as efficient as the enzyme digestion method because antibody treatment only 
partially removed the target peak, even for standards. This partial elimination is caused by the 
specificity of the chosen antibody that targets D-Glu-G-protein although antibody can recognize 
small-size molecules like D-Ala
38
. Thus, the antibody can bind not only D-Glu but also D-Asp 
that is structurally similar to D-Glu. Beside the unspecific binding problem, it is difficult to keep 
the activity of the antibody once it is conjugated to MB followed by precipitation of the 
antibody-MB conjugate during its storage. Thus, the enzyme digestion is preferred for sample 
treatment to identify D-AA peaks although it is not entirely impossible that antibody can be used 
for D-AA peak identification by completely eliminating a target peak
39
.  
 Another way to confirm peak identity is to change separation mode significantly. Thus, 
NACE is potentially useful for peak identification because analytes may behave differently from 
their behavior in aqueous solution. Indeed, some non-aqueous separation solutions showed 
different migration pattern from aqueous separation buffer even with the same concentrations 
and types of chemical additives were used (Figure 6.9). Perhaps, this difference was largely 
influenced by analyte-CD interaction mediated by solvent molecules that could (or could not) fill 
the space between analyte and CD effectively. Bulky chemical additives such as quinine may 
cause this difference for other reasons, e.g. saturating solubility of solvent so that analyte could 
spend to bind with CD for longer time. When migration pattern of NACE separation varies from 
that of aqueous separation, target peaks can be indirectly identified, e.g. analyzing peak intensity 
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ratio of an enantiomeric molecule pair such as L- and D-Asp. This indirect identification method 
particularly works for enantiomers because chemical and physical properties are similar; the 
response of enantiomers at the detector is expected to be the same (or perhaps with a negligibly 
small difference) so that the peak ratio of enantiomers is kept the same regardless of solvent. 
Also, the chance of successfully separating enantiomers increases if NACE is employed to have 
multiple migration patterns. This is important because aqueous and non-aqueous separation 
modes work complementary to achieve chiral separation of particular analytes that are difficult 
to separate with one separation mode but easy in another separation mode. Even more, it is 
meaningful to have multiple separation options to work with biological samples; unknown peak 
of a biological sample may interfere with the target peak in one separation mode but it may not 
happen in different separation mode. 
 Besides CE-LIF, CE-ESI-MS can be an attractive option for analyte identification. 
Although the chiral separation method for CE-ESI-MS described above suffered from reduced 
chiral separation capability and sprayer tip corrosion, CBI-AA peaks were still detectable. To 
improve the performance of chiral CE-ESI-MS, separation solution need to be modified to obtain 
more chiral resolution of the peaks. Ideally, modified separation solution contains smaller 
concentration of cyclodextrin to reduce the chance of sprayer corrosion. Chance of sprayer 
corrosion might be also reduced by lower voltage applied to electrosprayer
40
 or by using sprayer 
made of material other than steel
41
. If sprayer corrosion is alleviated, it may result in less analyte 
adsorption on the inner surface of sprayer tip
42
 so that limit of detection is improved.   
 As a distinct topic, DAACP analysis worked well for standard DAACPs and amino acid 
residues obtained by short VPH. However, these methods did not show evidence of DAACPs for 
intact peptide or at the residue level while the same samples analyzed by tandem MS showed the 
evidences of DAACPs
21
. A possible reason for the different results obtained by CE-LIF and 
tandem MS analyses may be dilution of the samples for labeling peptides or amino acids for CE-
LIF methods. Alternatively, it may be that the samples were not labeled appropriately because 
derivatization processes require suitable pH of sample solution. Since it was difficult to measure 
or estimate pH of LC-fraction or mixture of LC-fraction and derivatization buffer due to the 
small volume samples, uncertain pH could result in that the expected limits of detection for the 
peptides and residues were not achieved. 
  125 
 Overall, the enzyme methods and several NACE separation modes have been well-
established. Therefore, these methods are used for subsequent experiments with biological 
samples. Notably, the enzyme digestion method proves our confidence in peak identification 
using CE-LIF measurements. In contrast, NACE method provides useful separation results that 
can be used for indirect peak identification by comparing with the information given by aqueous 
CE separation and sample spiking by authentic chemicals. The methods related to DAACP are 
established for standard samples. Additional enhancements and optimization are needed before 
this method will be effective for characterizing D-AAs from  biological samples. 
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6.6  Figures 
 
Figure 6.1. D-Glu peak suppression by antibody. (a) 1 µM each of CBI-D/L-Glu and Asp 
(control); (b) the same standard with 1 hour incubation with the antibody-MB conjugate; (c) 12 h 
incubation; (d) 1 h incubation with the overnight-stored antibody-MB conjugate. (e) comparison 
of 1 µM each of CBI-D/L-Glu and Asp with the antibody-MB conjugate treatment (black), the 
antibody treatment (red), and no treatment (blue). (f) the expected molecular part of the antigen 
that is recognized by the antibody. 
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Figure 6.2. Digestion of D-Asp and D-Glu by DAspO. (a) Digestion was carried out with 0.4 
mg/mL DAspO, 40 µM flavin adenine dinucleotide (FAD), and 50 µM each of D/L-Glu and D/L-
Asp in 32 mM sodium pyrophosphate (pH 8.0) at 37°C. D-Asp was quickly oxidized while D-Glu 
required better condition for digestion. (b) Modified condition for D-Glu digestion: 1.7 mg/mL 
DAspO, 670 µM FAD, and 167 µM each of D/L-Glu and D/L-Asp in 34 mM sodium 
pyrophosphate (pH 8.0) at 37°C. 
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Figure 6.3. NACE separation solutions for CE-LIF. (a) Development scheme of new NACE 
separation solutions. Representative separation results of (b) 10 µM each glycine (Gly), D/L-
serine (Ser), D/L-Glu, and D/L-Asp with (top) PEO coating and (bottom) PEGylation coating by 
separation buffer of 50 mM α-CD, 25 mM CS, 50 mM QN, pH* 9.1 in FA. (c) 1 µM each Gly, 
L-Ser, L-Glu, L-Asp, and L-alanine (Ala) and 0.5 µM each D-Ser, D-Glu, D-Asp, and D-Ala were 
separated by (top) separation solution of 50 mM α-CD, 25 mM CS, 50 mM QN, pH* 9.1 in FA 
and (bottom) 1 µM each Gly, D/L-Ser, D/L-Glu, D/L-Asp, and D/L-Ala were separated by 
separation solution of 10 mM α-CD, 40 mM HP-γ-CD, 45 mM CS, 30 mM QN, pH* 5.6 in FA. 
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Figure 6.4. D-Glu in ganglia samples from Aplysia. NACE separation of cerebral ganglia 
without F- and C-clusters (a) with no DAspO treatment and (b) after 1 h treatment. D-Glu and D-
Asp peaks were removed by DAspO treatment.  Separation solution: 50 mM α-CD, 25 mM CS, 
50 mM QN, pH* 9.1 in FA. (c) A summary of relative amount of D-Glu and D-Asp found in 
different part of Aplysia ganglia.  
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Figure 6.5. Comparison of chiral separation by CE-ESI-MS (a and c)and CE-LIF (b and d). 
(a) and (b) used uncoated capillary and separation solution of 0.65 mM QA-β-CD, 4.35 mM QA-
γ-CD, and 5 mM ammonium formate in 50:50 (v/v) water:methanol. (c) and (d) used capillary 
with PEGylation coating and separation solution of 20mM γ-CD, 40mM AmFm in water. 
Applied voltage: (a) -21 kV (b) -27 kV (c) -20 kV, and (d) -15 kV across 80 cm capillary. 
Hydrodynamic pressure was applied to (b) by maintaining 8.5 cm inlet-side elevation. Other 
separation settings are described in the main text. Samples: (a) 50 µM each CBI-D/L-Asp and Ser, 
(b)-(d) 1µM each CBI- L-Asp and Ser and 0.5 µM each CBI-D-Asp and Ser.  
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Figure 6.6. Comparison of hydrolyzation methods. FMRFa standard sample with different 
hydrolyzation methods were separated in the same condition. Separation solution was 40 mM β-
CD and 60 mM SDC in 200 mM borate, pH 9.5. The box below the electropherograms 
summarizes isomerization of amino acid residues. Phe or F is phenylalanine, Met or M is 
methionine, and Arg or R is arginine. Lower case d before F, M, or R represent the peak is D-
isomer of the corresponding amino acid residue. 
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Figure 6.7. Separation of biological sample obtained through VPH method applied to 
buccalin B LC-fraction. The sequence of buccalin B is GLDRYGFVGGLa and L-isomer of 
buccalin B residues are identified above except arginine that is not favorably derivatized by 
NDA in pH 9.5. The peaks denoted as * are unknown peaks in the samples with VOH treatment.  
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Figure 6.8. DAACP separation with PBSE labeling. (a) The structure of PBSE and derivatized 
peptide. (b) Separation results of PB-peptides by 40 mM β-CD and 60 mM SDC in borate buffer 
(β-CD/SDC) and 150 mM HP-β-CD and 50 mM SDC in Tris-borate buffer (HP- β-CD/SDS). 
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Figure 6.9. Comparison of aqueous CE and NACE separations. Different chiral resolutions 
of CBI-amino acids were observed in formamide separation buffer (top) and aqueous separation 
buffer with 200 mM borate (bottom) of similar chemical additive compositions. Both separation 
solutions contained 60 mM SDC and 40 mM β-CD. 
 
 
